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Abstract 
Rationale 
Hypoxaemia plays a role in the aetiology of abnormal skeletal muscle function in Chronic 
obstructive pulmonary disease (COPD) via abnormal protein synthesis and mitochondrial 
function.  Patients exhibiting exercise-induced desaturation (EID) have exercise 
intolerance, perhaps a consequence of muscle hypoxia.  Ambulatory oxygen therapy 
(AOT) is indicated in these patients; however the evidence is derived from single 
assessment studies.  This thesis explores the role of longer term AOT and whether it 
favourably alters skeletal muscle gene expression in patients with COPD and EID. 
Methods 
A 12 week randomised controlled trial of AOT against air in 25 patients with COPD and 
EID was undertaken. Participants underwent skeletal muscle biopsies and exercise 
assessments.   In parallel a systematic review of published literature from 1980-2014 for 
trials in which AOT was compared to placebo in COPD was completed. 
Results 
The systematic review showed that AOT had no statistical effect on improving exercise 
capacity (6 minute walk or endurance shuttle walk tests); p=0.44 and p=0.29 respectively. 
Gene set enrichment analysis show the KEGG pathways of oxidative phosphorylation, 
PPAR signalling and fatty acid metabolism to be up-regulated following AOT (q<2%) in the 
clinical trial of AOT versus Air. 
Conclusion 
AOT has limited long term benefit in improving functional exercise capacity.  It may 
however favourably alter gene expression in patients with COPD and EID. 
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Chapter 1 
Introduction 
Chronic Obstructive Pulmonary Disease 
 
Chronic obstructive pulmonary disease (COPD) is the 4th leading cause of death 
worldwide and predicted to be the 3rd by 2020 with the incidence of the disease 
increasing due to persistent exposure to risk factors and an ageing population(1). In the 
UK 900,000 people are diagnosed with COPD with another 2 million remaining 
undiagnosed(2).  Estimated costs to the NHS are in the region of £800 million in direct 
healthcare costs(2), highlighting the need to study the disease to develop effective 
treatments. 
 
1.1 Diagnosis and Clinical Features 
 
COPD is characterised by airflow limitation that is usually progressive and not fully 
reversible(3).  The airflow limitation is a consequence of chronic inflammation which 
affects both small airways and lung parenchyma resulting in narrowed small airways and 
loss of elastic recoil.  Tobacco smoking is recognised as an important aetiological risk 
factor(in the Western world) however, only 15-20% of smokers develop clinically 
significant disease(4).  From this it can be inferred that development of the disease is due 
to the interplay between genetic susceptibility and inhalation of noxious particles, most 
commonly from cigarette smoke but also environmental pollutants.   
Diagnosis is based on physiological testing using post bronchodilator spirometry where 
the ratio between forced expiratory volume in the first second (FEV1) and forced vital 
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capacity (FVC) ratio is <70% in the presence of symptoms in individuals exposed to COPD 
risk factors(3).  The predominant symptoms are: 
• Dyspnoea which is generally progressive, persistent and worse with activity or exercise. 
• Cough-with or without sputum production. 
• Wheeze 
The use of fixed FEV1/FVC ratio of <70% has been suggested and used by the Global 
initiative for chronic obstructive lung disease (GOLD)(3) due to its relative simplicity; 
however this remains a controversial issue.  This is largely due to prevalence studies 
demonstrating disparity between the fixed ratio and lower limit of normal (the lower 5th 
percentile for reference population) when used for diagnosis.  The use of the fixed ratio 
may result in misclassification at extremes of age; an overestimation and 
underestimation of disease in older and young older patients respectively(5, 6).  The use 
of the lower limit of normal is less likely to cause this and in contrast to GOLD and 
National institute for clinical excellence (NICE)(7) is used by the ATS (American Thoracic 
Society) and ERS (European Respiratory Society). 
The classification of severity airflow obstruction is based on the reduction in FEV1 
compared to that predicted by age, gender and height.  The FEV1 % predicted (table 1) is 
standardised, as such classification of severity in the UK-NICE guideline (7) is the same as 
that across America and Europe; ATS/ERS guidelines(8). 
Although airflow obstruction has been used in several international guidelines to define 
severity, its use alone to define symptoms and management is outdated has been 
replaced by multicomponent system(3). 
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GOLD Severity FEV1% 
1 Mild >80% 
2 Moderate 50-79% 
3 Severe 30-49% 
4 Very Severe <30% 
Table 1.1: Severity of airflow obstruction by FEV1% 
This multicomponent system incorporates; exacerbation history, quality of life and level 
of dyspnoea.  Quality of life and dyspnoea scores are quantified by the COPD assessment 
tool (CAT) and modified Medical research council (mMRC) respectively. The former is 
scored out of 40 and the mMRC out of 4 with higher scores indicating greater symptoms. 
Patients are categorised by these features (figure 1) into groups; A to D which indicate 
both their symptom burden and exacerbation history. Group A low symptoms and 
exacerbation burden, group B high symptoms and low exacerbation burden, group C low 
symptoms and high exacerbation burden and group D high symptom and exacerbation 
burden. 
 
 
 
 
 
 
 
 
 
 
mMRC 0-1 mMRC >2 
CAT <10  CAT >10 
 
Figure 1.0:  Severity Matrix COPD 
 
C 
 
D 
 
A 
 
B 
Exacerbation 
history 
>2 or >1 leading to hospital 
admission 
0 or 1 not leading to 
hospital admission 
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1.1.0 Pulmonary Physiology in COPD 
 
Physiological testing is the cornerstone of COPD diagnosis. FEV1 has been well 
characterised in patients with COPD.  A lower FEV1% predicted is associated with worse 
health related quality of life (HRQoL) (9), symptom burden (10), a higher frequency of 
exacerbations(11) and mortality(12).  The transfer factor for carbon monoxide 
(DLCO/TLCO) measures gas exchange within the lungs.  Although less well characterised 
than FEV1, impairment of DLCO may indicate patients with reduced exercise capacity and 
those more likely to be affected by exercise induced desaturation (13).  KCO (transfer 
factor per alveolar volume) is a measure of DLCO corrected for alveolar volume and 
normally indicates parenchymal involvement, which in the context of COPD suggests 
emphysema (section 1.1.1).  The measurement of lung volumes FRC (functional residual 
capacity), TLC (Total lung capacity) and RV (residual volume) can be made using body 
plethysmography or inert gas dilution.  In COPD these often reveal evidence of gas 
trapping suggested by raised RV:TLC ratio, raised RV and reduced inspiratory capacity. 
Physiological testing via lung function can also indicate bronchodilator reversibility or 
small airways disease.  Bronchodilator reversibility: an increase of 12 % and at least 
200ml in FEV1 is common in COPD and more likely when the FEV1 is low(3).  It may also 
suggest coexisting asthma which is likely to have implications for long term management. 
Small airway disease, measured physiologically by mid expiratory flow (FEF25-75%) is of 
interest in COPD as changes in their function may be the earliest signs of disease. Cross 
sectional studies have previously shown that even if pathology was present in the small 
airways FEV1 remained normal however as pathology progressed FEV1 subsequently 
declined(14). 
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1.1.1 Heterogeneity in COPD 
 
Despite its spirometric definition COPD is a heterogeneous disease that encompasses a 
spectrum of clinical presentations which may co-exist. Typical clinical presentations 
include chronic bronchitis and emphysema. 
Chronic bronchitis is classically defined as chronic cough with sputum production for at 
least 3 months of 2 consecutive years(15).  It is caused by mucus overproduction and 
hypersecretion by goblet cells.  This contributes to airflow limitation by causing luminal 
obstruction and altering airway surface tension increasing the tendency for them to 
collapse(16). Those affected are more likely to have a more rapid decline in lung 
function(17) and higher exacerbation(18) frequency than those without chronic 
bronchitis. 
Emphysema is the destruction of alveolar walls with permanent abnormal enlargement of 
airspaces distal to terminal bronchioles(19).  The use of computed tomography (CT) has 
enabled this diagnosis to be made in vivo from radiology in addition to its widely 
accepted histological diagnosis.  Emphysema may be subdivided in its distribution on high 
resolution computer tomography (HRCT) both in terms of its relative geographic position 
within the lung as a whole (upper vs lower) or position relative to the secondary 
pulmonary lobule (centrilobular vs panlobular)-figure1.1/1.2.  
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Figure 1.1 and 1.2: CT thorax cross sectional images of emphysema.  
Centrilobular 
emphysema 
Panlobular 
emphysema 
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Emphysema in patients with COPD is typically upper lobe predominant and centrilobular 
in its distribution.  However in Alpha one anti trypsin deficiency, a condition where there 
is a genetic predisposition to emphysema, it is typically lower zone predominant and 
panlobular(20).  The distribution of emphysema within the lung may represent distinct 
clinical phenotypes. For example, lung volume reduction surgery a procedure which has 
been shown to improve functional and quality of life outcomes(21) is only effective for 
upper lobe predominant emphysema.  It is important to note that both chronic bronchitis 
and emphysema; quantified by computer tomography can occur in the absence of airflow 
obstruction(16, 22).  
1.2 Pathogenesis 
 
The pathogenesis of COPD is complex and not completely understood. It involves several 
inflammatory cell types, molecular pathways and cytokines.  Over the years a number of 
overarching concepts contributing to COPD pathogenesis have emerged; inflammation, 
protease anti- protease imbalance and oxidative stress. 
1.2.0 Inflammation 
 
The concept of inflammation is supported by studies demonstrating increased 
inflammatory cell infiltrate in the sputum, bronchoalveolar (BAL) fluid and lung biopsies 
of patients with COPD compared to healthy controls (23). There is some evidence to 
suggest that the intensity of the inflammatory cell infiltrates correlates with the degree of 
disease progression(24-27). The key inflammatory cells implicated are macrophages, 
neutrophils and cytotoxic T cells (CD8+)(28, 29). 
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Cigarette smoke activates macrophages to release pro-inflammatory mediators including 
interleukin 8 (IL8), tumour necrosis alpha (TNF-α) as well as chemoattractants such as 
leukotriene B4 (LTB4)(28, 29). 
TNF-α enhances inflammation by activating nuclear factor Kb (NF-kB) which switches on 
the transcription of inflammatory genes(28).  Serum levels of TNF-α have been shown to 
be higher in patients with COPD than controls and are also associated with the loss of fat 
free mass (FFM) in patients with COPD(30). 
Macrophages also secrete protease enzymes; matrix metalloproteinases (MMP), 
cathepsins and neutrophil elastase (largely taken up from neutrophils) which degrade the 
extracellular matrix within the lung.  Furthermore, macrophages from patients with COPD 
have greater elastolytic activity at baseline than smokers without COPD which is 
accentuated by cigarette smoke(31, 32). Neutrophils migrate to the lungs and respiratory 
tract under the chemotactic influence of IL8 and LTB4.  They secrete oxidants as well as 
serine proteases most commonly neutrophil elastase which contributes to alveolar 
destruction.  The chemotaxis of neutrophils in COPD has been shown to be aberrant (33) 
which may potentiate the amount of destruction that occurs during migration in the lung.  
CD8+ T cells are found in increased numbers of the lung parenchyma of patients with 
COPD(34, 35).  Although their role in COPD pathogenesis is not fully understood they 
have the ability to induce alveolar cell apoptosis by activating FAS-FAS ligand 
pathways(36).  Majo et al demonstrated association between CD8+ cells and apoptosis of 
alveolar cells in patients with emphysema(36).  The interaction between inflammatory 
cells and cytokines in the pathogenesis of COPD is summarised in figure 1.3. 
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Figure 1.3: Inflammatory cells and cytokines involved in COPD pathogenesis. 
 
1.2.1 Protease-Anti protease imbalance 
 
The concept of protease-anti protease balance contributing to pathogenesis in COPD 
arose from early studies of alpha one antitrypsin (AAT) deficient patients developing early 
onset emphysema(37).  AAT is an anti-protease which predominantly acts to block the 
action of neutrophil elastase (NE).  Proteases break down the extracellular matrix within 
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the lung parenchyma.  One of the key components is elastin and its destruction reduces 
the elasticity of the lung parenchyma and development of emphysema.  There are two 
main types of proteases; serine (NE and proteinase 3) and cysteine (cathepsins and 
MMPs). Each protease is inhibited by one or more anti-proteases (table 1.2).  
Protease Antiprotease 
Neutrophil elastase 
Proteinase 3 
α 1 antitrypsin  
Cathepsins Secretory leukoproteinase inhibitor 
MMPs Tissue inhibitors of MMPs 
Table 1.2: Protease and antiproteases involved in the pathogenesis of COPD.   
MMPs are increasingly recognised to play a role in COPD pathogenesis(38).  They 
predominantly break down collagen and gelatin; other components of the extracellular 
lung matrix and are inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs) 
(39, 40).  Previous studies have demonstrated increased activity of MMP 9 in the lung 
parenchyma of patients with COPD (40).  Animal models support the role of MMPs in 
pathogenesis as mice lacking MMP9 are protected from small airway fibrosis(41) and 
those lacking MMP12 are protected from cigarette smoke induced emphysema(42). 
1.2.2 Oxidative Stress 
 
There is considerable evidence for the role of oxidative stress in patients with COPD (43-
45).  Oxidative stress occurs when reactive oxygen species (ROS) such as O2- and hydrogen 
peroxide are produced in excess or overwhelm that of natural antioxidant defence 
mechanisms.  This has deleterious effects and results in damage to tissue by mechanisms 
including lipid peroxidation, tissue remodelling and DNA damage.  Cigarette smoke is a 
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potent source of oxidants, which can directly damage elastin and collagen(46).  
Furthermore, the interaction between cigarette smoke, epithelial cells and inflammatory 
cells increases ROS formation(47, 48).  In addition to the direct damage of elastin and 
collagen, oxidants detrimental effects are also mediated by inactivating anti-proteases 
but activating certain MMPs(49, 50).   
Studies have shown several markers of oxidative stress, for example, hydrogen peroxide, 
myeloperoxidase (51)and markers of oxidative tissue damage, such as 8-isoprostane 
1(52)to be elevated in exhaled breath or exhaled breath condensate from patients with 
COPD.  The major antioxidants in the respiratory tract lining fluid include reduced 
glutathione, uric acid, vitamin E and ascorbic acid(53). Reduced glutathione production is 
upregulated in response to oxidative stress in healthy subjects(54). Interestingly studies 
have shown that glutathione is elevated in BAL fluid from chronic smokers(43, 55) which 
may suggest that up-regulation of antioxidants occur in an attempt to restore the oxidant 
anti-oxidant imbalance. 
 
1.3 Management 
 
The treatment of COPD is multifaceted; involving patient education, exercise programs 
and pharmacological therapy.  The main aims are to improve patient’s health status, 
exercise tolerance and reduce patient’s symptoms and exacerbations.  Patient education 
of the disease process and recognition of changing symptoms are important.  Acute 
exacerbations are defined as a sustained increase in cough, dyspnoea or sputum 
production beyond normal day to day variability and have deleterious impacts on patient 
health related quality of life (HRQoL) and lung function(56, 57). Thus patient recognition 
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of changes in their symptoms can allow prompt treatment to mitigate these effects. The 
roles of both pharmacological and non-pharmacological therapies are discussed below. 
1.3.0 Non Pharmacological 
 
Pulmonary rehabilitation (PR) is an individualised exercise programme with an 
educational component and it has established itself as a key non-pharmacological 
treatment in COPD.  In the UK PR programmes are of between 6-12 weeks duration and 
usually include 2 supervised sessions per week.  PR is undertaken in stable patients and 
recent evidence suggests benefit in those who have had recent exacerbations(58). The 
principal training methods are endurance (continuous or interval) and resistance training 
as the benefit in muscle strength from a combination of training modalities seem to be 
greater than endurance alone(59). The educational components of PR are targeted 
towards smoking cessation, general information about COPD, self-management and 
decision making during exacerbations(3). 
1.3.1 Pharmacological 
 
The spectrum of pharmacological therapy within COPD is widening(60); however the 
mainstay of treatment encompasses bronchodilators, inhaled corticosteroids and oxygen 
therapy.  Bronchodilators are broadly subdivided into Beta 2 agonists and anti-muscarinic 
agents. Their action reduces dynamic hyperinflation by reducing air trapping and 
facilitates emptying of the lungs.  This improves inspiratory lung volumes which reduces 
breathlessness and improves exercise capacity.  Short and long acting bronchodilators are 
used, with long acting bronchodilators having the advantage of once to twice daily 
administration which has been suggested to aid compliance. Inhaled corticosteroids (ICS) 
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target airway inflammation and although this is thought to be predominantly neutrophilic 
in COPD(61) inhaled corticosteroids have been shown to reduce acute exacerbations and 
improve HRQoL when combined with long acting bronchodilators when the FEV1 % 
predicted is <60%.(62).  These therapeutic agents are introduced in a stepwise manner 
either as symptoms or airflow limitation progresses(7) (figure 1.4). 
The advent of dual bronchodilators LABA/LAMA is likely to change current guidance.  
They have been shown to be superior to combination LABA/ICS in improving 
breathlessness and to reduce exacerbations in landmark clinical trial (63). 
Notwithstanding current guidance, the concept of defining a patient’s “treatable traits” 
has developed over the last few years(64).  This management strategy guides treatment 
based on a phenotypic presentation or understanding of the causal biological pathway. 
As such patients with chronic bronchitis defined as persistent productive cough for more 
than 3 months over 2 consecutive years benefit from the addition of anti-inflammatory 
agents such as Roflumilast to their treatment regimen whilst COPD patients without this 
phenotype do not.  Roflumilast has subsequently been licensed by NICE as add on to 
triple therapy (LABA/ICS and LAMA) in this group.  Review of previous clinical trials have 
shown that LABA/ICS treatment is likely to be more effective in reducing exacerbations 
and slowing lung function decline in COPD patients with eosinophilic inflammation(65) (a 
peripheral blood eosinophil count of >2%); a hypothesis that has been tested in recent 
clinical trials(63, 66).  Here, the higher blood eosinophil count acts as a biomarker to 
identify patient who would derive greater benefit particularly from the inhaled 
corticosteroid in the LABA/ICS combination. Thus, the use of guidelines in concert with 
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the concept of treatable traits is likely to offer greater precision in the choice of therapy 
for patients and will likely translate to improved outcomes. 
SAMA or SABA as required
FEV1%>50 FEV1%<50
LABA LAMA LABA/ICS LAMA
LABA/ICS
LABA/ICS and LAMA
OFFER 
THERAPY(STRONG 
EVIDENCE)
CONSIDER THERAPY
 
 
Figure1.4: Nice guidelines for COPD management. SAMA-short acting muscarinic antagonist, 
SABA-short acting beta 2 agonist, LABA-long acting beta 2 agonist, LAMA-long acting muscarinic 
antagonist. 
 
1.3.2 Interventional 
 
Interventional treatments are used as an adjunct to both pharmacological and non-
pharmacological treatments or in advanced disease in certain patients.  Lung volume 
reduction surgery (LVRS) is a procedure whereby parts of the lung are resected in an 
attempt to reduce hyperinflation.  It has been shown to improve exercise capacity and 
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survival in patients with upper zone predominant emphysema and low baseline exercise 
capacity(67). Other selection criteria for LVRS include FEV1%>20, DLCO>20% and PaCO2 
<7.3kPa(21).  Lung volume reduction using similar selection criteria can also be 
undertaken bronchoscopically; a recent meta-analysis (68) concluding it is a safe and 
effective treatment for patients with emphysema.  Finally, lung transplantation in 
carefully selected patients with very severe COPD transplantation has been shown to 
improve functional capacity and quality of life outcomes (69).  
 
1.4 Oxygen in COPD 
 
Hypoxaemia is a hallmark feature of COPD as in many individuals gaseous exchange 
becomes more impaired as the disease progresses, leading to hypoxemia at rest and in 
some individuals on exercise alone.  The mechanisms underlying this are multifactorial 
and include diffusion limitation, ventilation/perfusion mismatches and shunting. Despite 
current advances in medical therapy oxygen therapy in the form of LTOT (long term 
oxygen therapy) is the only treatment in COPD which has demonstrated a mortality 
benefit in hypoxaemic individuals with COPD(70, 71). Oxygen therapy however, is also 
used outside of this setting to improve exercise capacity or ameliorate dyspnoea.  Use of 
oxygen therapy during exercise has been shown to reduce dynamic hyperinflation and 
thus reduce dyspnoea(72).  Other postulated mechanisms by which supplemental oxygen 
exerts beneficial effects are reductions in anaerobic respiration of peripheral muscles; 
indicated by reduced blood lactate levels(73) and possibly reduced peripheral 
chemoreceptor activity(74). 
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1.4.0 Long Term Oxygen Therapy (LTOT) 
 
The indications to use oxygen therapy in hypoxaemic individuals with COPD are derived 
from two landmark trials (NOTT, MRC) published in the 1980’s(70, 71).  The MRC was a 
randomised controlled trial (RCT) designed to assess whether the use of supplementary 
oxygen for 15hrs/day compared to no supplemental oxygen conferred a survival 
advantage over 3 years. 87 participants with severe COPD, hypoxaemia (PaO2<8kPa) and 
hypercapnia (PaCO2>7.4) were enrolled in which oxygen was administered at 2L/min or 
higher (to achieve PaO2>8kPa).  Results showed improved survival in those randomised 
to oxygen vs controls (p<0.05).  The NOTT trial provided further evidence for the use of 
supplementary oxygen in resting hypoxaemia in COPD.  This RCT assessed whether 
continuous supplemental oxygen improved survival compared to nocturnal oxygen alone.  
Enrolled participants had resting hypoxaemia (PaO2<7.3) or PaO2<8kPa in the presence 
of polycythaemia or electrocardiographic evidence of right heart strain. Results 
demonstrated a survival advantage with continuous oxygen compared to nocturnal 
(P=0.01).  Of the important secondary outcomes there was significant reduction in 
polycythaemia and pulmonary vascular resistance(75).  Kaplan Meier survival curves for 
the LTOT trials are shown in figure 1.5. 
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Figure 1.5: Kaplan Meier survival  curves for LTOT trial. COT-continuous oxygen therapy, NOT-
nocturnal oxygen therapy COT-Continuous oxygen, NOT-Nocturnal oxygen MRC (Medical 
research council) 
 
Long term oxygen therapy (LTOT) is indicated in stable hypoxaemic COPD when:  
• PaO2 ≤ 7.3kPa 
• PaO2 7.3-8 kPa in the presence of pulmonary hypertension, nocturnal hypoxaemia 
or raised haematocrit. 
In contrast to the above studies supplemental oxygen therapy has not been shown to 
improve survival in moderately hypoxaemic individuals with COPD(76) (77).   The study by 
Albert et al(77) which initially recruited patients with stable resting desaturation was re-
designed to include those with exercise induced desaturation. It did not demonstrate any 
benefit of supplementary oxygen with regards to improved survival, reduction in hospital 
admissions or exercise capacity. 
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1.4.1 Ambulatory Oxygen Therapy (AOT) 
 
Ambulatory oxygen therapy, defined as the use of supplementary oxygen during activities 
of daily living is used in patients who meet LTOT criteria(78).  It is also used in non-
hypoxaemic patients whom exhibit exercise induced desaturation if there is a 
demonstrable improvement in exercise capacity or breathlessness scores(78).  
Theoretically the use of ambulatory oxygen therapy (AOT) to mitigate desaturation on 
exertion may improve oxygen utilisation in peripheral muscles, reduce dynamic 
hyperinflation (79) and reduce dyspnoea. 
Exercise Induced desaturation 
Patients with COPD experience exercise induced desaturation (EID) in an unpredictable 
fashion, exhibiting variability both in the magnitude and temporal onset of EID with 
mobilisation(80). There is no uniform definition of EID however in the UK it is defined as 
fall in oxygen saturations by ≥4% (nadir ≤90%)(81).  In the United States the nadir of <88% 
is used and forms the basis for the remuneration policy employed by Medicare. Evidence 
from two studies(82, 83) suggests that the prevalence of EID increases with increasing 
severity of airflow obstruction and is associated with worse HRQoL, higher mortality and 
is likely to contribute to exercise limitation in COPD(82).  A number of studies(80, 84) 
have attempted to propose predictors of EID in COPD without consistent consensus.  
Nevertheless, reduced pulmonary physiology (DLCO<50% and FEV1<45%), baseline 
arterial PaO2 <10kPa and female gender seem to be the strongest predictors of EID(80). 
The precise mechanism leading to arterial hypoxaemia and desaturation is thought to be 
due to altered pulmonary physiology. During exercise both ventilatory demand and 
ventilatory workload are increased. Ventilation and perfusion within the lung are crucial 
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for normal arterial oxygen haemostasis.  This is deleteriously affected in patients with 
COPD either due to airflow limitation or parenchymal destruction; in those with co-
existing emphysema.   Low ventilation/perfusion ratio areas within the lung in addition to 
worsened alveolar deadspace significantly contribute to hypoxaemia in COPD especially 
during exercise(85, 86).  This is potentiated by dynamic hyperinflation which occurs 
during exercise and which worsens alveolar deadspace and thus hypoxia. Adverse 
pulmonary mechanics; raised inspiratory capacity and dynamic hyperinflation may 
contribute to sensation of breathlessness and exercise limitation(87). The impact of 
exercising muscle is also important.  A number of studies have demonstrated higher lactic 
acid generation at lower workloads in patients with COPD(88). Theoretically arterial 
hypoxaemia may exacerbate peripheral muscle oxygen utilisation, increase lactic acid 
production and cause peripheral muscle fatigue. This is supported in one study in which 
the degree of quadriceps fatigue correlated with peak oxygen utilisation(89). Interestingly 
muscle afferents in COPD have been shown to abnormal and may mediate enhance 
respiratory effort and perception of dyspnoea(90). Since AOT has some effect on dynamic 
hyperinflation and will improve arterial oxygenation in areas of V/Q mismatch and 
potential muscle oxygenation it may provide a means to improve exercise intolerance in 
selected patients. Increasing arterial oxygenation will also directly inhibit carotid body 
stimulation reducing the sensation of dyspnoea which has been shown to limit exercise 
capacity. 
 
AOT assessment 
In the assessment of ambulatory oxygen therapy exercise capacity is assessed using 
specific field tests.  The three main types of field tests are: 6 minute walk test (6MWT), 
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endurance shuttle walk test (ESWT) and incremental shuttle walk test (ISWT).  
Importantly cycle ergometry should not be used in the assessment of ambulatory 
oxygen(81).  The magnitude of desaturation in greater in walking field test compared to 
cycling. The study by Mahler et al demonstrated that enhanced alveolar ventilation and 
subsequent higher partial pressure of alveolar oxygen during cycle ergometry minimised 
the decrease in arterial oxygen and thus had a “protective” effect against 
desaturation(91). 
 
Field Tests 
The 6MWT is a practical and simple test which has been shown to be a predictor of 
mortality and morbidity in COPD(92).  The test is self-paced in which participants are 
instructed to walk up and down a 20-50metre corridor for 6 minutes.   
“The object of this test is to walk as far as possible for 6 minutes. You will walk back and forth in this 
hallway. Six minutes is a long time to walk, so you will be exerting yourself. You will probably get out of 
breath or become exhausted. You are permitted to slow down, to stop, and to rest as necessary. You may 
lean against the wall while resting, but resume walking as soon as you are able.”(93) 
 
The distance walked, number of stops, Borg dyspnoea score (table 1.3) and oxygen 
saturations (baseline and nadir) are noted.  There is some debate regarding whether a 
practice walk is needed as in many individuals there is a learning effect with an increase 
6MWD on the subsequent by as much as 17% of the original distance (93).  Evidence 
suggest that the 6MWT is less sensitive to change with interventions such as 
bronchodilators(94, 95)than other exercise tests. Nevertheless it provides robust 
information of functional status and relates well to activities of daily living (96). As stated 
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although there has been debate about the use of practice walks updated guidance 
suggest that they should be undertaken if the 6MWT is being used to measure change 
over time(97). 
Borg Score  
0 
0.5 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Nothing at all 
Very, very slight (just noticeable) 
Very slight 
Slight (light) 
Moderate 
Somewhat severe 
Severe(heavy) 
 
Very Severe 
 
 
Very, very severe (maximal) 
Table 1.3 Borg Dyspnoea Scale 
The ISWT uses a 10m course and the walking speed is externally paced by signals from an 
audio cassette.  Incremental increases in walking speed occur each minute, to a point at 
which the test is terminated because of; breathlessness, the inability to sustain the 
walking speed or achievement of 85% of maximal heart rate.  The ISWT has been shown 
to produce maximal response in patients with COPD(98)and is responsive to interventions 
of exercise training. The ESWT is also externally paced whereby participants walk for as 
long as possible performed at a speed 85% of their maximal capacity (calculated from 
ISWT).  The test enables participants to achieve standardisation of exercise intensity 
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which is sustained until limited by symptoms.  The ESWT has been shown to be 
repeatable(99) and responsive to interventions of exercise training and bronchodilators. 
During ambulatory oxygen assessments participants will perform one of these tests on air 
and is then repeated with oxygen therapy. Patients are deemed to qualify for AOT if there 
is a 10% increase in exercise capacity or reduction in Borg score of 1(81) .  
The mode of delivery of ambulatory oxygen therapy is variable but can broadly be divided 
into liquid oxygen against compressed cylinder oxygen delivered via continuous flow 
devices or oxygen conserving devices.  Oxygen conserving devices can be further 
subdivided to Demand oxygen devices (DODs) or Pendant reservoir cannula (PRC).  DODs 
deliver oxygen during inspiration only whilst PRC are nasal cannulae with a storage 
reservoir which increase the proportion of oxygen delivered during inspiration 
theoretically allowing lower flow rates to be used. Oxygen conserving devices deliver 
oxygen only during inspiration whereas continuous flow systems deliver oxygen 
throughout the respiratory cycle.  Cylinder types can also be further subdivided into 
lightweight systems some of which are refillable.  During the test the participant should 
carry, push or pull the ambulatory oxygen system alone without help from the assessor.   
Ambulatory oxygen does have an acute effect in improving exercise capacity.  The 2005 
Cochrane review demonstrated clear benefit of short term ambulatory oxygen in 
improving exercise capacity in moderate to severe COPD(100).  However, the review 
encompassed mainly single assessment studies whereby patients underwent a modality 
of exercise testing with ambulatory oxygen and compressed air generally over 1 day.  
Whether the acute improvement in exercise capacity is sustained has not been proven. 
Interestingly in a subsequent Cochrane review in which ambulatory oxygen was 
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evaluated in the context of pulmonary rehabilitation programs no benefit was 
demonstrated(101).  Given that most pulmonary rehabilitation programs run longer than 
6 weeks it is unclear whether longer term use of ambulatory oxygen still provides 
continued benefit in improving functional exercise capacity. 
1.4.2 Short Burst oxygen Therapy (SBOT) 
 
SBOT is used for the symptomatic relief of dyspnoea in patients who do not meet LTOT or 
AOT therapy criteria.  It is commonly used prior to or following short periods of exertion 
in patients with COPD.  The use of SBOT is controversial and studies investigating its 
effects have been limited by inconsistency of exercises performed, outcome measures 
and heterogeneous patient selection.  Nevertheless early studies by Woodcock et al(102) 
and Evans et al(103) have shown some benefit of SBOT by improving submaximal 
treadmill distance and shortened dyspnoea recover time post exercise respectively.  
Interestingly however, the study by Evan et al(103) specifically tested the reproducibility 
of SBOT’s ability to improve dyspnoea recovery time. Despite testing the subjects who 
responded to SBOT initially reproducibility was poor.  Subsequent studies(104-106) have 
shown no benefit in SBOT’s ability to improve dyspnoea, exercise tolerance (6MWT) or 
HRQoL.  The largest of these (106) in which 78 patients recently discharged following an 
exacerbation were randomised to SBOT (2l/min) or cylinder air for 6 months to be used 
to relieve distressing dyspnoea.  SBOT did not improve HRQoL, hospital readmission or 
healthcare utilisation. 
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1.5 Muscle disease in COPD 
 
Although characterised by airflow obstruction many patients with COPD exhibit systemic 
manifestations such as muscle dysfunction, loss of fat free mass, cardiovascular 
disease(107), diabetes(108), depression and osteoporosis(109). Skeletal muscle 
dysfunction is characterised by reduced muscle strength and or endurance(3) and is an 
important systemic manifestation in COPD which contributes to the morbidity of the 
disease.  Although SKMD can occur in upper limbs and to some degree respiratory 
muscles this thesis concentrates on skeletal lower limb muscle in patients with COPD. 
One of the key observations is that SKMD is likely to have a detrimental impact on 
exercise capacity.  Exertional dyspnoea and reduction in exercise capacity are common 
features of COPD, however studies of patient self-reported symptoms suggest that 
perceived leg effort or fatigue were the predominant limitations to their exercise ability 
(110, 111).  Interestingly in lung transplant recipient patients exercise capacity remains 
abnormally low, by as much as 50% predicted workload for age and gender despite 
normalisation of lung function(112).  Also pulmonary rehabilitation provides significant 
improvement in exercise capacity without significant change in lung function (59).  These 
observations taken together suggest that SKMD plays an important role in exercise 
performance.  Furthermore SKMD is recognised to contribute independently of lung 
function to mortality (113). Reduced mid-thigh cross sectional area and quadriceps 
strength have been shown to be strong predictors of mortality after adjusting for FEV1, 
age and sex(113-115).  Finally SKMD is likely to contribute to poor health status and 
healthcare utilisation (116, 117). 
25 
 
1.5.0 Skeletal Muscle Structure 
 
Skeletal muscle is composed of a motor unit (figure 1.6); the muscle fibre and its 
innervating motor neuron.  The functional units of muscle are called sarcomeres. Within 
each sarcomere are the myofibrillar proteins myosin and actin. The myosin heavy chain in 
the head region contains an adenosine triphosphate (ATP) binding site for the conversion 
of ATP into ADP (adenosine diphosphate) and phosphate. The heavy chains contain the 
myosin heads that form cross bridges with actin which facilitate muscle contraction. 
Muscle fibres are classified as fast twitch or slow twitch depending on their contractile 
speed.  Fast twitch fibres are further subdivided to fast twitch fatigue resistant, fast 
twitch intermediate and fast twitch fatigable.  This classification corresponds broadly to 
muscle fibre identification by myosin heavy chain (MHC) immunoreactivity and 
myofibrillar ATPase staining (table 1.4). 
Fibre ATPase MHC 
Slow twitch I MHCI 
Fast twitch fatigue Resistant IIa MHCIIa 
Fast twitch Fatigable IIb MHCIIx/d 
Fast twitch Intermediate IIx 
Table 1.4: Muscle fibre classification 
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Figure 1.6: The muscle motor unit 
1.5.1 Clinical Observations 
 Skeletal Muscle Strength and Endurance 
 
Skeletal muscle strength is defined as the capacity of the muscle to generate force.  This 
is mediated by three factors; “cross sectional area of the muscle fibres within the motor 
unit, the number of muscle fibres innervated by the motor neuron and the specific force 
of the muscle fibre” (118).  In general fast twitch intermediate and fatigable generate 
more force per unit area than slow twitch or fast twitch fatigue resistant (118).  The force 
generated by each fibre depends on intracellular calcium levels, which are important for 
sarcoplasmic reticulum excitation/contraction and also neuronal activation.  The 
contribution of neuronal activation to muscle strength is important as in the early stages 
of muscle training gains in strength are mediated by neural adaptation rather than by 
muscle hypertrophy(119). In COPD especially in severe disease quadriceps muscle 
strength may be reduced by as much as 30%(120, 121). This difference however 
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disappears when quadriceps strength is normalised to mid-thigh cross sectional area, 
implying therefore that muscle atrophy is important in determining muscle strength. 
Endurance relates to the ability of muscle to maintain a certain force over time; normally 
a percentage of maximal force or exercise capacity.  In health, oxygen delivery and 
utilisation rather than ventilatory function or compromised cardiac function limits 
endurance. This is a complex interplay between muscle enzyme concentration, capillarity, 
mitochondrial volume density and bioenergetics(118).  The energy for skeletal muscle 
contraction is derived from the de-phosphorylation of ATP.  Low intracellular stores of 
ATP mean that skeletal muscle can only sustain contraction for a few seconds before this 
is replenished or further ATP generated.  One mechanism is the breakdown of 
Phosphocreatine to phosphate and creatine mediated by the enzyme creatine kinase.  
Other more effective mechanisms are that of oxidative phosphorylation, Krebs Cycle and 
to a lesser degree glycolysis.  Skeletal muscle endurance is also perturbed in COPD.  A 
number of studies have reported a reduction in quadriceps endurance in patients with 
COPD(122, 123).  Interestingly in one of these studies(122) an artificial stimulation 
protocol was used thus negating the impact of central fatigue. 
Fatigue is another determinant of endurance, of which two types are recognised; central 
and peripheral. Central fatigue indicates contractile reserve within the muscle, in that 
additional force can be generated by nerve stimulation in the event of voluntary “task 
failure”. Peripheral fatigue implies that there is no contractile reserve within the muscle 
which may be due to transmission at the neuromuscular junction, muscle membrane or 
muscle microfilaments. There is a complex interplay between central and peripheral 
fatigue which is not completely understood.  In health several studies(124, 125) have 
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shown that arterial oxygen concentration affects central fatigue and peripheral fatigue; 
both deleteriously affected by hypoxia. The study Amann et al suggest that central 
fatigue is likely to be the dominant of the two(126).  The study used varying oxygen 
concentrations; normoxia to hypoxic (15% Oxygen) to show that exercise performance 
switches from a predominantly peripheral origin during normoxia to central origin during 
increasing hypoxia.  It is highly likely that lowered arterial oxygen concentration may play 
a role in limiting exercise tolerance in patients with COPD in this manner. 
1.5.2 Laboratory observations 
Muscle mass 
 
Muscle mass homeostasis is a dynamic process involving a balance between protein 
synthesis and protein degradation. Protein synthesis is mediated by hypertrophic 
signalling and protein degradation by atrophic signalling and autophagy.  Anabolic 
hormones, namely Insulin and Insulin like growth factor 1 (IGF-1) stimulate the 
hypertrophic signalling pathway.  They act on the phosphoinositide 3 kinase (PI3 K)/AKT 
(protein kinase B) pathway(127).  AKT in its phosphorylated form stimulates mTOR 
(mammalian target of rapamycin) which can promote protein synthesis by activation of 
the 70-kD ribosomal S6 protein kinase (p70S6K) and inhibition of 4E-BP1 (eukaryotic 
initiation factor 4E binding protein respectively.  AKT also directly inhibits glycogen 
synthase kinase-3 (GSK-3), which represses protein synthesis(127).  Atrophy signalling is 
mediated by the ubiquitin proteasome pathway.  Proteins identified for degradation are 
attached to ubiquitin by E3 (ubiquitin ligating) enzymes of which two have been 
identified; atrogin 1 (muscle atrophy F-Box) and MuRF1 (muscle ring finger-1).  MuRF1 is 
stimulated upstream by pro-inflammatory cytokines largely mediated by NF-kB.  Atrogin 
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1 is stimulated upstream by p38 MAPK (mitogen activated kinase), for which oxidative 
stress and inflammation are potent stimuli.  There is a degree of cross talk between these 
pathways.  AKT can block protein degradation by down regulating atrogin 1 and MuRF-1. 
This is mediated by phosphorylation of FoxO (forkhead box O) transcription factor.  The 
atrophy and hypertrophy pathways are summarised in figure 1.7. 
 
AKT
PI3K
GSK-
3 mTOR
p70S6
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E4-
BP1
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ULK-1
AUTOPHAGY
HYPERTROPHY SIGNALLING
Insulin, IGG-1, 
ATROPHY SIGNALLING
Inflammation, ROS,  Myostatin
PROTEIN SYNTHESIS PROTEIN DEGREDATION
Ubiquitin
Proteasome
 
                Activates        Blocks  
Fig 1.7: Hypertrophy and atrophy signalling pathways in muscle. 
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Autophagy is a constitutively active process in limb skeletal muscle(118) and is the 
process whereby proteins are degraded in autophagsomes.  Autophagosomes are then 
delivered to the lysosomes for degradation of their contents.  Autophagy is initiated by 
the ULK1 complex which is under the control of AMP-activated protein kinase (AMPK) 
and mTOR pathways(128). mTOR phosphorylates and inactivates ULK1 thus inhibiting 
autophagy whilst AMPK is able to inactivate mTOR.  Although the role of autophagy in 
skeletal muscle has not fully been elucidated, it has been shown to significantly induced 
in limb muscles following denervation(129). 
 SKMD-pathological changes 
 
One of the key structural alterations in skeletal muscle of patients with COPD is that of 
skeletal muscle atrophy and fibre type shift.  Fat free mass (FFM) a surrogate for skeletal 
muscle mass is reduced in COPD (130).  The degree of thigh muscle mass lost is relatively 
greater to that of the whole body weight indicating a preferential loss of muscle tissue 
over body tissue in COPD.(121).  Cross sectional studies have demonstrated increased 
mRNA levels of atrogin-1 and MuRF-1 (131, 132) in the quadriceps of COPD patients 
compared to controls indicating upregulation of atrophic pathways.  This however bore 
no relationship to quadriceps function and no difference was found between COPD 
patients with and without preserved muscle mass(127). COPD patients have a reduction 
in proportions of type 1 accompanied by increased proportions of type IIx fibres, which is 
contrary to what occurs in normal ageing(118).   The reduction in type 1 fibres mirrors 
disease severity. Gosker et al(133) showed that as FEV1 declined the proportion of type 1 
fibres also decreased.  Type I fibres are advantageous as they confer greater oxidative 
capacity.   Thus the switch to type IIx fibres may explain the increased fatigability and 
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reduced endurance in COPD limb muscle.  Although there is atrophy of all fibre types 
there is some evidence (134) to suggest this occurs preferentially in the type IIx fibre.   
Capillary density is important in skeletal muscle as oxidative metabolism is dependent on 
the capillary supply and mitochondrial volume density. Capillary density has been shown 
to be reduced in COPD muscles(135), although this is not a consistent observation(136). 
This is may be due to the heterogeneity between studies with some carried out in the 
context of exercise training(136) which is known to improve capillarity.   
Finally mitochondrial bioenergetics is altered in COPD with reduced oxidative enzyme 
capacity. Key enzymes involved in oxidative phosphorylation such as citrate synthase and 
succinate dehydrogenase have been shown to be reduced(137, 138).  In line with these 
observations expression of PGC-1 α/PPAR (peroxisome-proliferator activated receptors) a 
regulator of cellular oxidative phosphorylation is reduced in the musculature of COPD 
patients(139). 
 
1.6 Aetiology of SKMD in COPD 
 
1.6.0 Inflammation 
 
Inflammation is a key concept in COPD and its role in the pathogenesis of the disease has 
been discussed.  It may play a role in SKMD. Whether this is a consequence of systemic 
and or local inflammation is not completely clear, however a number of studies lend 
support that pro-inflammatory cytokines can adversely affect skeletal muscle growth.  A 
number of pro-inflammatory cytokines have been implicated in pathogenesis; TNFα, IL-6 
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and IL-8. Spruit et al demonstrated an inverse relationship between quadriceps muscle 
strength and serum IL-8 levels(140) albeit during exacerbations, whilst elevated IL-6 levels 
are associated with radiological evidence of quadriceps wasting in COPD(141).  In vitro 
studies have shown that TNFα induces apoptosis in skeletal muscle cells and 
myoblasts(142).   
The predominant system whereby inflammation is thought to exert its role is by 
increasing activity of the ubiquitin proteasome pathway via NfkB activation.  A significant 
increase in NfkB nuclear binding has been observed in the limb muscles of patients with 
COPD(143).  Furthermore NfkB has been shown to directly inhibit MyoD a myogenic 
regulatory factor involved in satellite cell differentiation (144). 
1.6.1Hypoxia 
 
In health, under hypoxic conditions such as at altitude functional, structural and 
morphological changes in skeletal muscle occurs which bear close resemblance to those 
found in COPD(145).  Skeletal muscle endurance, strength (145, 146) and muscle mass 
are reduced.  Furthermore, evidence suggests that hypoxia may have a deleterious 
impact on the force of muscle contraction by altering the strength of actin myosin cross 
bridges(147).  Interestingly in this study(147) this contractile dysfunction was reversed 
following re-oxygenation.  Hypoxia has been shown to impair the mTOR pathway(148) 
and thus may contribute to muscle wasting.  Further to this, in vitro studies have shown 
that hypoxia inhibits myoblast differentiation by degradation of MyoD(149).  In addition, 
tissue hypoxia could also play a part in determining systemic inflammation as there is a 
relationship between extent of arterial hypoxaemia and circulating levels of TNF, and its 
receptors, in COPD patients(150).  It may also potentiate oxidative stress (118, 147).  
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During hypoxia the transcription factor hypoxia inducible factor-1α (HIF-1α) is increased 
which may alter bioenergetic pathways by down and up regulating oxidative and 
glycolytic enzymes respectively(151).  This also mirrors the reduced proportion of type I 
fibres observed in hypoxaemic patients with COPD compared to non-hypoxaemic 
patients(152).  Finally studies of limb muscle transcriptomic have shown this to be altered 
in COPD. Turan et al(153) used a systems biology approach and found a failure of COPD 
limb muscles to co-ordinate several tissue remodelling and bioenergetics pathways.  This 
study suggested that this abnormality is linked to an altered expression of histone 
modifiers with correlate with peak oxygen uptake, suggesting that cell hypoxia may play a 
role in SKMD through epigenetic mechanisms. 
1.6.2 Oxidative Stress 
 
Mitochondria are the main sources of RNS (reactive nitrogen species); derived from nitric 
oxide and ROS production especially during skeletal muscle contraction.  In normal 
skeletal muscle ROS and RNS are produced at relatively low levels and play a positive role 
in normal physiological functions(154).  However, in COPD the production of these 
species is at a higher rate and overcomes the antioxidant ability; this is particularly true 
during acute episodes of exercise or following exacerbations(118). ROS and RNS may 
particularly target key contractile proteins and enzymes within muscle fibres(154); 
implicated in myosin heavy chain carbonylation and reduced creatine kinase enzymes. 
Further evidence for the role of oxidative stress is provided by the identification of 
oxidation of proteins, DNA and lipids.  COPD patients exhibit higher levels of 
peroxidation, oxidized glutathione, and protein carbonylation in the blood and limb 
muscles(137, 155-157).  The level of oxidative stress may have functional implications.  
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Koechlin et al(158) reported that use of n-acetylcysteine (an anti-oxidant) improved 
quadriceps endurance time in patients with COPD.  Oxidative stress may also relate to 
protein degradation and hence muscle loss.  ROS species are able to trigger the ubiquitin 
proteasome and p38 MAPK pathways (118, 154). 
1.6.3 Disuse 
 
Physical activity in patients with COPD is generally lower than the average population 
with more having a sedentary lifestyle (159).  This is thought to be a consequence of 
deconditioning heralded by the dyspnoea spiral in which patients do not exert 
themselves to avoid dyspnoea which in turn causes a decline in fitness. Physical inactivity 
leads to a number of adaptive changes in skeletal muscles including altered mitochondrial 
biogenesis, reduced capillary density and reduced proportions of type I muscle 
fibres(139, 160) which all negatively affect strength and endurance.  The preferential loss 
of thigh muscle mass relative to body weight may suggest that muscles that are least 
used, in this case the lower limbs are more susceptible.  This is supported in some respect 
as other muscles such as the diaphragm shows an increase in oxidative capacity and 
increase in type I fibres in severe COPD(161). 
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1.7 Aims 
 
This thesis sets out to explore 3 aims  
1) Systematic review of ambulatory oxygen in COPD  
2) To assess the biological response in muscle to oxygen therapy  
3) To assess the clinical effectiveness of ambulatory oxygen therapy in patients with 
exercise induced desaturation. 
Aim 1 
Chapter 2 of this thesis will set out the methodology to explore aim 1. Ambulatory oxygen 
therapy (AOT) is widely used currently in patients with COPD who exhibit exercise 
induced desaturation, if they show an improvement in exercise capacity or 
breathlessness scores.  The evidence base for this has come largely from single 
assessment studies whereby AOT was evaluated generally over one day by a given 
exercise modality(100).  In general the majority of trials to date have shown that use of 
ambulatory oxygen in this setting is likely to be of benefit, in terms of duration of 
exercise, dyspnoea on exertion and quality of life.  The caveat to this is that many of the 
trials in the review had small sample sizes with no generation of power calculations with 
reviewers describing methodological quality as low(100). A subsequent review evaluated 
AOT use in the context of pulmonary rehabilitation and found no clear benefit(101).  
Since most pulmonary rehabilitation sessions last longer than 6 weeks the longer term 
benefit is doubtful and has not been clinically proven.  Despite this, continued 
prescriptions for AOT occur on the basis of eligibility tests demonstrating benefit but 
without knowledge of its longer term efficacy.  Furthermore, it remains less clear 
36 
 
whether domiciliary ambulatory oxygen use is beneficial and whether there are long term 
gains with regard to exercise capacity or quality of life in the patients who use it in this 
way.  Finally, neither of the reviews explored the economic impact of AOT which in the 
current climate of assessing cost effectiveness of interventions is an important factor.  
Thus, there are several unanswered questions; does the acute effect of ambulatory 
oxygen on exercise capacity persist? Does use of AOT provide clinical benefit in a 
domiciliary setting and is AOT cost effective?    Using 3 linked systematic reviews specific 
objectives were to explore the: 
1. The clinical effectiveness of long term ambulatory oxygen therapy (defined by more than 
6 weeks duration) in patients with COPD exhibiting EID or exertional dyspnoea who do 
not meet the criteria for LTOT. 
2. The relative clinical effectiveness of different methods of delivering ambulatory oxygen in 
COPD patients and the optimum mode of delivery of the intervention; 
3. The cost-effectiveness of ambulatory oxygen in COPD patients not on LTOT compared to 
usual care and the relative cost-effectiveness of different methods of delivering 
ambulatory oxygen. 
Chapter 3 details the results of the systematic review; whether AOT has any effect on 
exercise or quality of life outcomes.  It also discusses if the effects of AOT on exercise are 
field test specific. 
 
Aims 2 and 3 
Chapter 2 of this thesis also sets out the methodology and statistical methods used to 
investigate the skeletal muscle biological response and clinical effectiveness of AOT in 
patients with exercise induced desaturation (EID).  EID is defined as a nadir <88%(81) on 
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ambulation is common in patients with chronic obstructive pulmonary disease (COPD). It 
affects patients with advanced and less advanced disease with evidence suggesting that 
they have worse health related quality of life, mortality and exercise tolerance(83) than 
non-hypoxaemic patients who do not exhibit this phenomenon(82).  The reason for 
observed exercise limitation is unclear and hypotheses have been discussed in section 
1.4.1 but is thought to reflect muscle hypoxia exacerbated by exertion.  It is well 
established that hypoxia has a role in perturbing muscle function, e.g. impairing protein 
synthesis and myogenesis by inhibiting the mTOR pathway(148) and contributes to 
muscle wasting via degradation of MyoD(149).  Hypoxia has also been linked to 
mitochondrial dysfunction(151) and a reduction in the proportion of Type I muscle 
fibres(152), suggesting a reduced endurance exercise capacity, which may be 
exacerbated by the oxidative stress that is increased in skeletal muscle mitochondria on 
exposure to acute hypoxaemia(162).  Inflammation is a key concept in COPD with a 
number of cytokines (discussed in 1.6.0) implicated in underlying aetiology of skeletal 
muscle abnormalities. Whilst numerous studies have assessed the impact of AOT on 
exercise performance(163), none have assessed the longer term effect of AOT on skeletal 
muscle gene expression, systemic inflammation or physical activity.  This is explored via a 
12-week randomised controlled cross over trial with 2 week washout for which the 
methods and rationale of trial design are outlined in Chapter 2.  
Chapter 4 documents the clinical results from the randomised controlled trial and 
discusses the impact of AOT on functional exercise capacity, physical activity and the 
inflammatory cytokine response to AOT. 
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Chapter 5 documents the skeletal muscle response to oxygen which has never been 
investigated previously. The muscle biopsies were subject to microarray analysis to 
explore differentially expressed genes or gene sets between oxygen and air.  This enabled 
the identification of genes or gene sets involved in important skeletal muscle 
transcription.  A hypothetical network interaction has been created between the clinical 
data set including exercise capacity, systemic inflammation and quality of life and the 
transcriptional changes seen in skeletal muscle. 
Chapter 6 concludes the thesis. 
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Chapter 2 
General Methods 
 
2.1 Systematic Review  
 
The review had 3 objectives, the methods for which had a degree of overlap but will be 
described separately here.  As with all systematic reviews achievement of the objectives 
has been limited by the type and quality of the available published evidence. The 
objectives to assess were as follows: 
Objective 1 - The clinical effectiveness of ambulatory O2 in COPD patients not on LTOT 
compared to usual care. 
This was to determine the benefit of the addition of ambulatory O2 to treatment 
regimens. 
Objective 2- The relative clinical effectiveness of different methods of delivering 
ambulatory O2 in COPD patients not on LTOT. 
This was to determine the optimum mode of delivery of the intervention.  
Objective 3- The cost-effectiveness of ambulatory O2 in COPD patients 
This included the cost-effectiveness of ambulatory oxygen in those not on LTOT 
compared to usual care, and the relative cost-effectiveness of different methods of 
delivering ambulatory O2. 
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For each objective the methods below describe the types of study included in the review, 
the population, intervention, comparator and outcomes assessed. This is the standard 
format for systematic review questions according to Cochrane guidance 
2.1.0 Objective 1 Clinical Effectiveness of Ambulatory Oxygen compared to 
Usual Care 
 
Study Design 
Randomised Control trials (RCTs), non RCTs and Cross over studies have been included.  
All studies had a follow up duration of more than 6 weeks.  Previous reviews(100, 101) 
have either been of less than 6 weeks duration or single assessment studies limiting their 
ability to demonstrate longer term benefit. Therefore any study with duration of less than 
6 weeks was excluded.   
Population 
The population for this objective included adult (18 years or over) patients suffering from 
stable chronic COPD but not on LTOT.  The definition of COPD chosen was broad; any 
study description of patients defined as having COPD by spirometry (NICE)(7), radiological 
emphysema or chronic bronchitis, were included. ‘Stable’ was defined as not currently 
undergoing, or within 6 weeks of, an exacerbation of their disease. This definition was 
chosen because the majority of patients with exacerbations demonstrate recovery of 
symptom scores and lung function within this time frame(18, 164).   
Interventions   
Ambulatory oxygen therapy was defined as the use of supplemental oxygen during 
exercise and activities of daily living, consistent with the definition used in BTS guidelines 
(81).  
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Comparators 
There were several suitable comparators, all of which were equivalent to medical air. 
Thus compressed air or gaseous mix equivalent to air were suitable, provided they were 
administered via a similar route to the intervention. Only studies in which the treatment 
difference between study arms was purely due to use of ambulatory oxygen were 
considered. 
Outcomes   
The primary outcomes were exercise capacity as measured but not limited to 6MWT 
distance, shuttle test distance and maximal power tests.  Health related quality of life 
(HRQoL), rates of exacerbations, hospitalisation and/or health service utilization were 
also considered.  
2.1.1 Objective 2 Clinical Effectiveness of methods of delivering ambulatory 
Oxygen. 
 
The criteria for population, intervention and outcomes remained the same as objective 1 
with the inclusion of: 
• Patients who met LTOT criteria 
• Studies with follow up of any duration included. 
The rationale for this is as follows. The use of ambulatory oxygen delivery devices has 
largely been restricted to patients using LTOT given the evidence base supporting it, or 
other forms of supplementary oxygen. A number of studies(165, 166) have demonstrated 
that a proportion of LTOT patients also experience EID.  The sole focus of this objective 
was to address the efficacy of the delivery device; thus included studies would compare 
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device against device and not ambulatory oxygen against placebo the above patient 
group and study duration were included. 
Comparator 
Any alternative method of delivering ambulatory oxygen to that of the intervention arm 
was considered a suitable comparator.  Only studies where the difference between study 
arms was purely due to variation in mode of ambulatory oxygen delivery were included. 
Such variation could be due to the equipment (portable cylinders, liquid canisters, oxygen 
conserving devices or concentrators) or the way the oxygen is inhaled i.e. interface, 
(mask or nasal cannulae). 
2.1.2 Objective 3-Cost-effectiveness of ambulatory O2 in COPD patients not on 
LTOT compared to usual care and the relative cost-effectiveness of different 
methods of delivering ambulatory O2 
 
The criterion for Population, Intervention and Comparator were the same as for aim 2-3 
combined. Study design and Outcome criteria were: 
Study Design 
Cost-analysis, cost-effectiveness, cost–utility and cost–benefit studies were targeted. 
Outcomes 
Assessment of impact on Quality of life and also cost judged by; incremental cost-
effectiveness ratios 
Criteria for Exclusion from this Review 
Studies which included patients on any other form of oxygen therapy (such as LTOT or 
short burst) apart from ambulatory oxygen therapy were excluded except if stated for 
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that objective. In addition studies that involved a mixed population were excluded, unless 
data on those patients relevant to the objective was presented and evaluated separately.  
2.1.3 Search strategy 
 
In order to maximise efficiency, two search strategies were undertaken. The literature 
search included the following databases; MEDLINE, MEDLINE in Process, EMBASE, 
Cochrane-(CENTRAL), Science Citation Index, NHS Economic evaluation database, PEDro, 
Health technology assessment database, ClinicalTrials.gov, CINAHL, and the Cochrane 
Airways specialised register.  Following this the references of each included study as well 
as any review articles found were searched for additional articles that may contain 
further studies. 
COPD treatment has changed considerably over the last 20 years(3, 8)consequently it 
may be that very old studies, particularly those that occurred prior to the introduction of 
LTOT, may not be relevant to current patients. For this reason, searches were started in 
1980, just prior to the publication of the LTOT trials(167, 168), as these were a landmark 
point in the therapy of COPD, whose results were widely accepted worldwide shortly 
after publication. No language restrictions were applied and both published and 
unpublished studies were sought (via contacting authors directly via email). The search 
strategy is outlined in Appendix 1.  
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2.1.4 Study selection, data extraction and risk of bias 
 
The search results were entered in to reference management software (Endnote X5, 
Philadelphia USA) and duplicate entries electronically and manually removed.  The 
remaining records were assessed for relevance to each objective in a two stage process. 
Stage 1 involved myself and another reviewer (Dr AM Turner) independently screening 
titles and where available abstracts against the inclusion/exclusion criteria to identify 
relevant studies. The aim of this stage was to remove irrelevant studies and thus those 
records on which a decision on relevance could not be made due to 
insufficient/ambiguous information. Full copies of all articles passing stage 1 were 
obtained. In stage 2, two reviewers (myself and Dr AM Turner) independently applied the 
inclusion/exclusion criteria to these articles.  Any disagreements between the other 
reviewer and I were resolved by consensus or through consultation with a third reviewer 
(Dr Chirag Dave).  A record of the studies excluded was kept along with the reason(s) for 
exclusion. 
One reviewer independently extracted and recorded essential information derived from 
each included study using a piloted data extraction form); a second reviewer checked all 
numerical data.For Objective 1 and 2 for each study, the data required on (but not limited 
to) the following was recorded: Design, completeness of follow up length of follow up; 
country of origin; study design; sample size; patient inclusion and exclusion criteria; 
patient characteristics; intervention/comparator, adherence/compliance, outcome 
measures; statistical methods employed; findings, effect sizes and associated uncertainty. 
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For Objective 3 data on the following were sought, type of design/analysis and features 
relevant to this, patient characteristics; intervention/comparator and outcomes were 
quality of life, costs and incremental cost-effectiveness ratios.  
The Methodological quality of the included RCTs was appraised by using the Cochrane 
risk of bias framework(169); for the comparative studies assessing the adequacy of 
sequence generation, allocation concealment and blinding for non-RCTs such as the 
observational studies (prospective and retrospective cohort study) were appraised using 
appropriate domains of the same tool. The Jadad Scale(170) was also used to assess 
methodological quality. 
2.1.5 Statistical Methods 
 
All trial data was combined using Review Manager 5.2 (Cochrane Collaboration). For 
objective 1 and 2, meta-analysis was undertaken for studies comparing the same 
interventions for key outcomes where clinical and methodological details between 
studies were considered to be sufficiently homogeneous. Thus, only results from the 
same exercise test protocols were analysed together (i.e. all constant power exercise 
tests, all functional exercise tests, all maximal exercise tests and all shuttle walk tests).  
Continuous data was synthesised as mean differences where possible as described below.  
Statistical heterogeneity was presented and interpreted using the I2 statistic. 
Data was pooled with the generic inverse variance method using change from baseline 
with the appropriate means and standard deviations for each study if provided. This 
method ensures larger studies with smaller standard errors are given greater weight than 
smaller studies with larger standard errors. For the studies that reported the pre and post 
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training means and respective standard deviations, in order to use the change in baseline 
outcome measure: 
1) The pre training means were subtracted from the post training means: 
2) The standard deviations (SD) for pre and post training were pooled. 
Pre and post-test exercise outcomes reported for both intervention groups were from 
tests performed on compressed air. 
A fixed effect was used in all analyses unless heterogeneity defined as (I2>30%) was 
present in which case a random effect was used. The meta-analyses are presented using 
forest plots from Review Manager 5.2.  Data which was not in a format suitable for meta-
analysis have been reported in narrative form. 
2.2 Clinical Trial General Methods 
 
The OM-COPD (oxygen for muscles in COPD) trial was a single centre double blind 
randomized crossover trial comparing 12 weeks of an oxygen/nitrogen mix (equivalent in 
oxygen concentration inspired by the patient to air) to 12 weeks of oxygen, used when 
performing activity, in the patients described below.   
 
 
Patients were enrolled between September 2012 and April 2014.  The trial design 
diagram is shown in figure 2.1.  A mix equivalent to medical air, rather than medical air 
itself, was required to ensure that colouring of the cylinders could be done in a manner 
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which allowed complete blinding. Gases were provided at a flow rate of 2l/min and were 
not to be used for any more than 4 hours of activity per day. 
Subjects were randomized using the sequentially numbered, opaque sealed 
envelopes  SNOSE technique(171).  A crossover design was chosen to minimise 
differences due to inter-patient variability, which was likely to be greater than intra-
patient variability in this group over the time frame proposed(172). 
There was a washout of 2 weeks between interventions. The following were examined; 
HRQoL, activity levels, 6MWT distance, capillary blood gas, blood tests (for inflammatory 
cytokines) and spirometry pre and post intervention and muscle biopsy pre and post 
intervention. This resulted in 6 invasive procedures (3 biopsies, 3 ear lobe capillary blood 
gases, 3 blood tests) per patient – before the trial, after the first and after the second 
intervention. Activity monitoring and HRQoL were assessed at the mid-point and end of 
each intervention, together with a basic clinical assessment of general and respiratory 
health.  
Of the outcomes studied the primary outcome was change in gene expression in skeletal 
muscle.  The biological changes in muscle in response to exercise in patients with COPD 
have been investigated in several previous studies(153, 173).  Many of these have used 
training programmes akin to pulmonary rehabilitation; at least over 8 weeks looking 
specifically at target genes or proteins in relation to mitochondrial bioenergetics or 
muscle hypertrophy, atrophic pathways.  Eight weeks was sufficient to induce 
measurable changes between trained and untrained in patients with COPD.  The length of 
time trial participants were exposed to each intervention in the clinical trial is based 
around this training timeframe.  As it is accepted that training is more likely to be a more 
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potent stimulus to skeletal muscle change than standalone domiciliary activity a longer 
12 week rather 8 week period was used.  The hypotheses were that either oxygen 
upregulate genes/gene sets involved in mitochondrial biogenesis or skeletal muscle 
hypertrophy.  This based on either oxygen having a direct action on skeletal muscle, i.e. 
mitigating the desaturation which occurred on exertion or that use of AOT would 
encourage participants to be more active and thus have a beneficial effect on skeletal 
muscle.  As such a 2 week wash out period was used as this would give sufficient time to 
revert to “normal” activity.  
Whilst a key aim of this trial was to examine the systemic response to oxygen, and in 
particular how this systemic response might influence the muscle, it was not possible to 
power the microarray analyses hence these were deemed exploratory; they are 
described further in chapter 5.  Secondary outcomes were limited to exercise capacity, 
physical activity, quality of life and cytokine response. 
 
 
 
 
 
 
 
 
49 
 
Screening visit 
Spirometry, 6MWT
Enrolment visit 1 (week 1) Start of trial
Consent, allocation by SNOSE
QOL, HADS, blood gas, venous blood
Data collection for COPD phenotypes
Muscle biopsy
Blood collection before 
Pre trial activity monitor issued*
Visit 2 (1 week after visit 1): Collection of activity monitors 
IMP/placebo** dispensing
Visit 3 (6 weeks after 
starting IMP/placebo):
QOL
Clinical check
Activity monitor issued
Visit 4 (12 weeks; end of 
IMP/placebo)
Spirometry, 6MWT
QOL, HADS, blood gas, venous blood
Data collection for COPD phenotypes
Muscle biopsy
Bloods as before
Activity monitor issued*
1-2 
week 
break 
then 
dispens
ing of 
new 
product
Visit 5 (6 weeks after starting 
IMP/placebo)
QOL
Clinical check
Activity monitor issued
Visit 6 (12 weeks after starting 
IMP/placebo)
Spirometry, 6MWT
QOL, HADS, blood gas, venous blood
Data collection for COPD phenotypes
Muscle biopsy
Bloods as before
Activity monitor issued*
Follow up visit  (6 weeks after 
IMP/placebo end)
Post trial activity monitor issued
Collect monitor
QOL, HADS
Spirometry
 
 
Figure2.1: Trial design diagram. 
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2.2.0 Ethics and governance 
The trial was conducted in compliance with the principles of the Declaration of Helsinki 
(1996) and the principles of Good Clinical Practice (GCP). Prior to the commencement of 
the clinical trial I completed GCP in clinical trial management.  The trial protocol and 
initial ethical approval was undertaken by the PI in conjunction with me.  Subsequent trial 
management including but not limited to organising patient visits, data collection, 
completing adverse event forms, performing muscle biopsies, submitting substantial 
amendments and maintaining the trial master file was undertaken by me.  Development 
safety update reports (section 2.2.9) along with summary of product characteristics for 
medical oxygen were completed and sent to Medicines and Healthcare products 
regulatory agency (MHRA) on a yearly basis.  During the clinical trial a number of new 
standard operating procedures (SOPS) were introduced by the sponsor.  Internal trial 
procedures were modified where possible to bring them in line with the new SOPS e.g. 
the delegation of adverse event reporting to trial PI/investigators by sponsor.  Adverse 
events were reported to the MHRA as part of the development safety update.  Suspected 
unexpected serious adverse reactions were reported to the sponsor.       
 
2.2.1 Participant selection 
 
Subjects were recruited from adult secondary care respiratory clinics  
.  Informed written consent was obtained from all participants 
prior to enrolment.  The clinical trial has ethical approval from the regional ethics 
committee ; key trial documents are shown in the appendix 2   
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25 patients with COPD were recruited. Enrolled patients had radiological emphysema or 
spirometrically defined COPD, according to British Thoracic Society standards (i.e. 
FEV1/FVC <0.7 and FEV1<80% predicted), and no co-morbidities that limited their 
mobility. All patients had oxygen saturations greater than or equal to 94% at rest and 
exhibited EID to less than 88% on exertion, as documented during a formal 6MWT.  All 
participants were clinically stable, defined as being more than 6 weeks since their most 
recent exacerbation. 
Exclusion criteria were as follows: 
• Age – less than 18 
• Immobile due to other medical conditions 
• On LTOT 
• Unable to understand or retain information 
• Uncontrolled angina symptoms 
• Evidence of clinically significant harm from oxygen therapy (decompensated type 
2 respiratory failure). 
All participants underwent the procedures described below as part of the clinical trial, 
which are summarized in the flowchart (Figure 2.1). 
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2.2.2 Demographic data 
 
Basic demographic data (gender and date of birth) was collected using a Case Report Form 
(CRF)-appendix 2.  The CRF included lung function at enrolment or that within 6 months of 
enrolment, the participant clinical phenotypes; delineated by bronchitis, emphysema or 
bronchiectasis and also medical research council (MRC) dyspnoea score. 
2.2.3 Spirometry and Arterial blood gas sampling 
 
All spirometry was performed by ARTP (association for respiratory physiology and 
technology) accredited respiratory physiologists within the lung function department  
.  Values obtained were compared to predicted values 
derived from standard reference equations for Caucasian adults (European Coal and Steel 
reference values).  Blood gas sampling was obtained using the earlobe blood gas sample 
technique; a well validated alternative to arterial blood gases(174).  If any subject had 
elevated carbon dioxide (>6kPa) on their baseline blood gas this was repeated after giving 
oxygen at 2l/min for 20 minutes in order to ensure that the subject was unlikely to come to 
any harm from using oxygen during the study 
2.2.4 Muscle biopsy 
 
Percutaneous needle biopsy offers a less invasive alternative to conventional open biopsy 
with satisfactory muscle yield (up to 300mg).  
Muscle biopsy was performed percutaneously from the lateral vastus lateralis under local 
anaesthesia  (2% lignocaine) and strict asepsis using the Bergstroms technique(175) shown 
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in diagram (figure 2.2 and 2.3) .  Samples were flash frozen using a dry ice acetone bath 
and subsequently stored at -80C. Samples were subsequently used for RNA extraction and 
microarrays, as detailed in 2.3.3 and 2.4. 
 
 
 
 
Figure 2.2. Equipment used for muscle biopsy sampling. 
 
 
 
 
 
Figure 2.3.  Bergstrom’s Procedure 
 
2.2.5 Blood Sampling 
 
Plasma was prepared from venous blood which was collected in EDTA blood tubes.  The 
venous blood was centrifuged at 1000g for 10mins with the resultant supernatant (plasma) 
stored in 0.5ml aliquots at -80oC. Plasma levels of TNF-α, interleukin 6 (IL-6), interleukin 8 
Bergstrom Needle 
Syringe 
Cleaning rod 
Lateral aspect of thigh (Vastus 
lateralis) 
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(IL-8) and interferon gamma (IFN-) were analysed using enzyme linked immunosorbent 
assays (Ebioscience). 
 
2.2.6 HRQoL and Activity Monitoring 
 
HRQoL was assessed using the COPD assessment test (CAT) accessed from 
www.catestonline.co.uk and the Hamilton Anxiety and Depression Scale(176).  Both of 
these patient reported questionnaires are well validated(177) and were chosen due to their 
ease and speed of completion. 
Activity monitoring was performed using Actigraph Tri-axial accelerometers.Participants 
wore the activity monitor around their waist for five days only removing it during sleep and 
bathing/showering.  Five days of home monitoring has been shown previously to 
adequately overcome day to day variation in activity levels at all stages in COPD(178) and 
provides a quantitative, objective measure of exercise capacity and energy expenditure in a 
real-life setting. Data was validated and scored using Actilife version 6 using the Freedson 
Adult cut off points(179) and expressed as vector magnitude units/min.  This accelerometer 
has been validated by the PROactive consortium to give an accurate indication of physical 
activity in patients with COPD(180). 
 
2.2.7 6MWT 
 
Participants underwent 6MWT in a 25metre corridor in accordance with ATS 
guidelines(93).  A practice 6MWT was not completed. Patients were encouraged every 
minute of the 6MWT using two phrases: “Keep up the good work” or “You are doing 
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well”. Patients were allowed to stop and rest during the test, but were instructed to 
resume walking as soon as they felt able to do so.  
 
2.2.8 Blinding, Treatment allocation and Statistical analysis 
 
There is a universal colour code for medical gas supply cylinders in the United Kingdom.  
Medical air cylinders are white and black whilst oxygen cylinders are white, therefore if 
standard cylinders were used blinding could not be achieved. For the purpose of the 
clinical trial all cylinders were white in colour.  A nitrogen/oxygen mix equivalent to air 
was used in place of air cylinders.  All cylinders were prepared by BOC Group PLC and 
delivered to the clinical trial pharmacy where they were labeled A and B.  The code break 
was held by the clinical trial pharmacist alone and was not revealed to trial investigators 
until the completion of the trial at the point when which results analysis was undertaken. 
Statistical analysis was carried out using SPSS version 22 Armonik, New York, IBM Corp. 
Normality of data was assessed using Spiro Wilk tests. Throughout the thesis normally 
distributed data is shown as mean (standard deviation) and non-normally distributed 
data as median (interquartile range).  All statistical analyses were completed prior to the 
un-blinding of treatment allocation by coding periods as Treatment A and B. For cross-
over trial data analysis clinical variables were firstly tested for evidence of carry over 
effects, i.e. the sum of values over both treatment periods were compared between 
those who received ambulatory oxygen first or air first and assessing whether there was 
significant difference between them.  Given that no carry-over effects were observed for 
clinical variables the order of treatment was not accounted for. Therefore change from 
56 
 
baseline for each treatment period was evaluated using paired statistical tests for 
primary and secondary clinical outcome data; T-tests and Wilcoxon tests were used for 
parametric and non-parametric data respectively.  
2.2.9 Trial monitoring and safety 
 
Trial monitoring was undertaken on more than 2 separate occasions by the trial sponsor.  
Monitoring visits were used to facilitate trial management and also to ensure procedure 
were in line with GCP.  All monitoring queries were discussed with the PI and co-
investigators with action points from monitoring queries dealt with by me. 
Adverse events (AEs) defined as any untoward medical occurrence in an enrolled subject, 
including occurrences which are not necessarily caused by or related to oxygen were 
recorded at follow up visits by myself and another co-investigator.   
2.3 Clinical Trial Laboratory Methods 
 
2.3.0 Enzyme linked immunosorbent assay 
 
This section describes the general technique used to measure plasma levels of IL-6, IL-8, 
interferon gamma and Tnf-α.  The specific details for each assay were followed from the 
manufacturers protocol.    
A quantitative sandwich ELISA was used in which the sample for analysis is quantified 
against the concentration of known standards; samples of predetermined concentration 
used to set up a standard curve.  The final fluorescence/colour generating step is specific 
to each ELISA is performed prior to reading the plate in standard microplate reader.  All 
samples were run in duplicate on a 96 well plate as shown in figure 2.4. The intra assay 
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coefficient of variation for samples was less than 10%.  If this was not the case samples 
were re-analysed. 
The sandwich ELISA process is demonstrated in figure 2.5. 
 
A Std1 Std1 S1 S1 S9 S9 S17 S17 S25 S25 S33 S33 
B Std2 Std2 S2 S2 S10 S10 S18 S18 S26 S26 S34 S34 
C Std3 Std3 S3 S3 S11 S11 S19 S19 S27 S27 S35 S35 
D Std4 Std4 S4 S4 S12 S12 S20 S20 S28 S28 S36 S36 
E Std5 Std5 S5 S5 S13 S13 S21 S21 S29 S29 S37 S37 
F Std5 Std6 S6 S6 S14 S14 S22 S22 S30 S30 S38 S38 
G Std6 Std6 S7 S7 S15 S15 S23 S23 S31 S31 Blank Blank 
H Std7 Std7 S8 S8 S16 S16 S24 S24 S32 S32   
 
Figure 2.4 Lab well   Std-standards of known concentration, S-samples (duplicated per 
well) 
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Fig 2.5  Sandwich Elisa process. 
 
 
A substrate is added and is converted by 
the enzyme to its detectable form 
The plate is coated with a capture 
antibody 
The sample is added and any antigen 
present binds to the capture antibody. 
A detection antibody is added which also 
binds to the antigen 
An enzyme linked antibody is 
added which binds to the detection 
antibody 
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2.3.1 RNA Extraction 
 
RNA was extracted from muscle biopsy samples using the QIAGEN RNAeasy kit 
(Manchester, UK) following the manufacturer’s protocol detailed below. This kit was 
chosen because it provides a reliable, relatively quick and consistent method of 
producing high quality RNA which can be used for downstream processes such as 
microarray analysis.  
1. “The muscle sample was homogenized by adding 700µl of QIAzol lysis reagent. 
2. The homogenate was incubated at room temperature (15-25oC) for 5 minutes. 
3. 140µl of chloroform was added to the homogenate and shaken for 15 seconds 
4. The mixture from step 3 was incubated at room temperature for 2-3 minutes 
before being centrifuged at 12,000g at 4oC. 
5. The upper aqueous phase was transferred to a new collecting tube using a Pasteur 
pipette where it was then mixed with 525µl of 100% ethanol. 
6. 700 µl of the sample including any precipitate was pipetted, into an RNeasy® Mini 
column in a 2 ml collection tube. This was then centrifuged at ≥8000 x g for 15 s at 
room temperature. Any follow through was discarded. 
7. The above step was repeated with the remaining sample. 
8. 700 µl of Buffer RWT was added to the RNeasy Mini column and centrifuged for 
15 s at ≥8000 x g. Any follow through was discarded. 
9. 500 µl of Buffer RPE was pipetted onto the RNeasy Mini column and centrifuged 
for 15 s at ≥8000 x g. Any follow through was discarded. 
10. 500 µl of Buffer RPE was added to the RNeasy Mini column and centrifuged for 2 
min at ≥8000 x g. 
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11. The RNeasy Mini column was transferred to a new 1.5 ml collection tube. 30–50 µl 
of RNase-free water was pipetted directly onto the RNeasy Mini column 
membrane and centrifuged for 1 min at ≥8000 x g before eluting.” 
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Muscle tissue 
        
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.6: RNA extraction process. 
 
 
Muscle tissue lyzed with QIAzol. 
Ethanol added to the muscle tissue 
homogenate and sample 
centrifuged 
Sample added to RNA column with 
addition of buffer and sample then 
centrifuged. 
Binding of RNA 
Sample washed and eluted to yield 
total RNA. 
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2.3.2 RNA amplification 
 
This section describes the process of RNA amplification used for microarray analysis. This 
was required as following RNA quality assessment (using absorbance) some of the 
extracted RNA was found to be degraded.  RNA amplification of intact and degraded was 
achieved using the Whole Transcriptome Amplification kit Sigma Aldrich (Gillingham, 
Dorset, UK).  This method has been validated(181) to effectively amplify degraded RNA 
maintaining transcripts levels representative of intact unamplified .  
Protocol for RNA amplication 
Library Synthesis Reaction 
The Library synthesis buffer and solution were thawed and mixed thoroughly.  Any 
precipitate was dissolved by briefly heating the mixture to 37oC. 
1. 100ng of RNA was added to 2.5µL of the Library Synthesis Solution. 
2. Nuclease-free water was added to bring the total to 16.6 µL. 
3. The resultant solution was mixed and incubated at 70°C  for 5 minutes then 18°C 
4. 2.5 µL Library synthesis solution, 3.9 µL Water and 2 µL of library synthesis 
enzyme were added. 
5. Incubated in  a thermal cycler using the following plan: 
18°C for 10 minutes 
25°C for 10 minutes 
37°C for 30 minutes 
42°C for 10 minutes 
70°C for 20 minutes 
4°C to hold 
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6. The 25µL samples were divided into 5 X 5µl aliquots on a fresh plate 
Amplification reaction 
The amplification mix and 10nM dNTP were thawed. 
1. A master mix was prepared by adding 301µL of nuclease-free water, 37.5µL 
amplification mix, 7.5 µL WTA dNTP mix, and 3.75 µL amplification enzyme. 
2. 70 µL of master mix was added to 5µL of the sample from step 6 of the library 
synthesis reaction 
3. Incubated in a thermal cycler: 
a. 94oC for 2 minutes 
b. 17 cycles of 94oC for 30 seconds and 70oC for 5 minutes 
c. End cycle 
4. The resulting WTA DNA was stored at -20oC. 
2.4 Microarrays 
 
The genetic expression microarray analysis was outsourced to the Biosciences 
department at the University of Birmingham at a cost of £4900.  This included dye 
labelling, hybridisation, array scanning and feature extraction.  The microarray 
experimental design was undertaken by myself.   
Two channel microarray microarrays were performed in a matched pair design i.e. each 
patient’s baseline muscle sample was hybridised along with their corresponding muscle 
sample following each intervention (baseline muscle sample with air treatment sample, 
baseline with oxygen treatment sample).  The two channel microarray design in this 
setting was significantly cheaper than a single channel analysis as the same information 
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could be gleaned using half the arrays.  Therefore, each array represented the log ratio 
between baseline condition and ambulatory oxygen/control and subsequent analysis 
comparing Air treatment vs Oxygen. 
Six hundred nanograms of cDNA from each sample were converted to labelled cDNA 
coupled to a fluorescent dye (Cy3 for baseline samples and Cy5 for samples following 
interventions) using Agilent SureTag labelling kit (Agilent, 5190-3400, Cheshire UK).  
These were competitively hybridised to 8x60k microarrays (Agilent Technologies G4851; 
Cheshire UK), washed and scanned, then data extracted from the scanned image using 
Feature Extraction (version 10.7.3, Agilent Technologies).  A schematic diagram explaining 
the microarray experiment procedure is shown in figure 2.7 
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Fig 2.7: Schematic diagram detailing the microarray process.   
mRNA is extracted from the muscle cells and labelled with two dyes (Cy3-green and Cy5-red) 
during the synthesis of cDNA by reverse transcriptase. The cDNA is hybridised to the microarray 
slide where each cDNA molecule representing a gene binds to the complementary DNA sequence.  
Following this the microarray slide is then excited with a laser a various wavelengths to detect the 
red and green dyes. Green spots indicate hybridisation with control samples only (muscle 
exposed to air), red hybridisation with test targets (muscle exposed to ambulatory oxygen), 
yellow hybridisation with both samples and black no hybridisation. 
Muscle exposed to 
Ambulatory oxygen 
Muscle exposed to 
Air 
mRNA extraction 
Dye labelling then hybridisation 
Excitation with laser and fixed image 
stored as a file 
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2.4.0 Normalisation 
 
Normalisation and subsequent microarray analysis was undertaken by myself in the 
program Bioconductor R.  
The package “marray” was used for microarray normalisation.  Normalisation is the 
process which eliminates sources of variation which affect microarray experiments.  
These can arise from differing quantities of initial mRNA between samples or differential 
dye labelling (dye bias).  The process of normalisation is based on the general principle 
that in a microarray experiment only a small proportion of genes will show changes in 
expression between two different conditions.  An MA plot is modified scatterplot used to 
visualise the red-green intensities from an array.  A, is the average log intensity of the two 
channels and M is the relative expression between the two channels also known as the 
log-ratio.  In an MA plot the points should be localised around the zero line in a situation 
where there are no technical artifacts.  Deviations from this zero line are due to non-
biological reasons and are therefore removed in the normalisation process.  The “loess” 
method is a within array normalisation method which was used to normalise the 
microarray data.  Figure 2.8 shows the same array MA plot before and after 
normalisation. 
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a)  
 
b) 
Figure 2.8: MA plots a) before and b) after normalisation 
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The significance of microarray package (SAM) was used to perform the microarray 
analysis of differential gene expression between ambulatory oxygen and air.  Exploratory 
analyses of microarray using gene set enrichment and principal component analysis are 
further explained in analysis of microarrays chapter 5. 
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Chapter 3. 
Systematic Review 
 
This review aims to clarify the longer term efficacy of AOT in those with EID and 
exertional dyspnoea when judged by outcomes measures of exercise capacity and quality 
of life.  It also evaluates whether the use of oxygen conserving devices is warranted.  
Previous reviews have been limited by their short duration (<6weeks) therefore, whether 
acute eligibility tests for AOT translate into longer term benefit is unclear. In addition, no 
previous review has evaluated the devices by which AOT is delivered. As discussed in the 
methods (section 2.1.5), only trials of similar exercise outcomes have been compared i.e. 
ISWT vs ISWT. Pulmonary rehabilitation (PR) studies have been analysed separately to 
domiciliary as they are not directly comparable.  Although the desired and hypothesised 
effect of AOT use in both PR and domiciliary studies was to improve exercise capacity 
analysing them together would conflate the effects of exercise and oxygen. 
Some of the results and text from this chapter have been published in the peer reviewed   
Journal of the COPD foundation: Chronic Obstr Pulm Dis (Miami). 2016; 3(1): 419-434.  
3.1 Results 
 
Twenty-three studies (620 patients) were included in the systematic review: nine studies 
evaluated the clinical effectiveness of ambulatory oxygen and thirteen studies evaluated 
the impact of the delivery device.  Generally the studies were small with primary 
outcomes focused on exercise capacity, Borg dyspnoea scores and exercise saturations.  
Figure 3.1 summarises the trial flow in the PRISMA format for reporting systematic 
reviews.   
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Figure 3.1 Prisma flow diagram
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3.1.0 Included Studies 
 
The included studies have been summarised in table 3.1 (clinical effectiveness) and table 3.2 
(delivery devices).   
3.1.1 Risk of Bias 
 
Allocation concealment, adequate sequence generation, blinding and Jadad score were used 
to assess this (table 3.3).  The Jadad score was poor in 12 of the 23 studies, good in 9 and 
excellent in 2 of the studies.  9 of the studies had adequate randomisation process; mostly 
undertaken by computer random number generation or Latin square sequencing.  Allocation 
concealment was adequate in 7 studies; undertaken by a mixture of central randomisation 
and the SNOSE technique.  Blinding was adequate in 6 studies; undertaken by blinding the 
assessor in the trial or use of identical cylinders arranged by the cylinder suppliers.  In a 
number of the studies especially the older (pre 1995) sequence generation, allocation 
concealment and /or blinding was unclear or high risk.  This information was not available in 
the individual manuscripts or after contacting the authors. 
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Author Inclusion Exclusion Study type Intervention Comparator Sample 
Size 
Methods Outcomes Results Summary 
McDonald 
et al(182) 
a)COPD 
b)PaO2>60mmH
g/8kPa 
c)clinically stable 
d)exertional 
dyspnoea 
sufficient to 
interfere with 
ADLs e)current 
non smokers 
a)symptomatic 
cardiac 
dysfunction, 
angina pectoris 
and locomotor 
disability. 
Crossover double 
blinded 
Oxygen 4l/min Air 4l/min 26 Unsupervised 12 
week domiciliary 
oxygen/air use 
a)6MWT 
b)Step test c)Borg 
Scores d)CRQ 
Small significant 
improvement in 6MWT 
on home O2. 
Improvement in all 
parameters of CRQ on 
home O2 compared to 
baseline. P<0.02 
Rooyacke
rs et 
al(183) 
a) COPD b) SpO2 
< 90% at 
maximal 
exercise c) > 
15mmHg 
/ 2.00kPa 
increase in 
alveolar-arterial 
difference in 
PO2 from rest to 
maximal 
exercise 
a) PaO2 < 
64mmHg / 
8.53kPa b) mean 
nocturnal SaO2 
< 90% c) 
mean 
pulmonary 
artery pressure 
> 25mmHg d) 
neuromuscular 
or 
cardiovascular 
disease 
Parallel un-blinded Oxygen 4l/min Air 12 Air 
group, 12 
O2 group 
10 week 
supervised PR 
program. 5 
sessions/week 
a)PFTs b)Maximal 
cycle ergometry 
(watts) c)Endurance 
cycling time 
d)6MWT e)CRQ 
f)Borg Scores 
Improvement in peak 
WR in air group only 
p<0.01. Improvement 
in 6MWT and total CRQ 
scores compared to  
baseline in both groups 
p<0.01  
Eaton et 
al (184) 
a)COPD b)<88% 
SpO2 on 
exertion 
c)resting 
PaO2>7.3kPa 
d)clinically 
stable 
a)limiting angina 
or significant 
musculoskeletal 
disability 
Crossover-double 
blinded 
Oxygen 4l/min Air 4l/min 41 Unsupervised 12 
week domiciliary 
oxygen/air use 
a)CRQ b)HADs c)SF-
36 d)6MWT 
e)Borg Scores 
No significant 
difference between 
groups in 6MWT p=0.4 
Improvement in total 
CRQ scores for home 
O2 period compared to 
home air p=0.002 
Emtner et 
al(185) 
 
 
a)COPD; FEV1 < 
50% predicted 
b) 45-80 years 
old 
a) Symptomatic 
cardiovascular 
co-morbidities 
or other disease 
Parallel double 
blinded 
Oxygen 3l/min Air 3l/min  14 O2 
group, 15 
Air group 
Supervised 7 
week exercise 
program with 3 
sessions/week 
a)Maximal cycle 
ergometry (watts) 
b)Constant power 
cycle ergometry 
Improvement in peak 
exercise tolerance test 
in both groups p<0.05. 
Endurance in constant 
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 c) clinically 
stable d ) PaO2 > 
55mmHg / 
7.33kPa at rest 
e)SpO2>88% 
during constant 
WR test 
that 
might contribute 
to exercise 
limitation b) 
regular 
participation in 
formal exercise 
program c) 
participation 
within a formal 
rehab program 
in last 2 years 
c)CRQ d)SF-36 
e)Borg Scores 
 
WR improved 
significantly in oxygen 
group compared to air 
group p<0.05. 
 
Nonoyam
a et al 
(186) 
 
 
 
 
a)COPD b)<88% 
SpO2 on 6MWT 
c)Dyspnoea 
interfering with 
ADLs 
a)LTOT 
 
 
 
N of 1 RCTs Oxygen 2l/min Air 2l/min 27 Unsupervised 6 
weeks domiciliary 
oxygen/air use 
a)CRQ b)SGRQ 
c)5MWT d)Borg 
Scores 
Improvement in 5MWT 
and Borg dyspnoea 
scores for home O2 vs 
home air p=0.04. 
No significant 
difference in HRQoL 
between home O2 or 
home air 
Janaudis-
Ferreira 
et al(187) 
a)COPD 
FEV1,70% 
b)<92% SpO2 on 
6WMT 
c)PaO2>8kPa at 
rest d)clinically 
stable d)not 
smoking 
6months prior 
to study 
a)severe cardiac, 
orthopaedic or 
neurological 
problems that 
would influence 
exercise 
performance 
b)LTOT 
Parallel single 
blinded 
Oxygen 5l/min Air 5l/min 10 Air 
group, 10 
O2 group 
Supervised 8 
week training 
program 
a)6MWT b)time 
<90% saturations 
c)Borg Score 
Improvement in 6WMT 
in both groups 
compared to baseline 
p<0.008 Air group and 
p<0.005 O2 group. 
Greater proportion of 
patients achieve MCID 
for 6MWT in air group 
p=0.01 
Moore et 
al(188) 
a)COPD 
b)PaO2.7.3kPa 
c) MRC 
dyspnoea>3 
 
a)Domiciliary 
oxygen use 
b)Participation 
in PR 
c)Locomotor 
Parallel double 
blinded 
Oxygen 6l/min Air 6l/min 75 cylinder 
air, 68 
oxygen 
Unsupervised 12 
weeks domiciliary 
oxygen/air use 
a)6MWT 
b)CRQ 
c)BDI/TDI 
d)HADs 
No significant 
difference between 
CRQ dyspnoea score, 
6MWT or BDI/TDI 
scores between groups. 
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Table 3.1: Clinical effectiveness of Ambulatory oxygen studies. 
5MWT5 minute walk test, 6MWT 6 minute walk test, CRQ chronic respiratory disease questionnaire, HADS Hamilton Depression and Anxiety Scale, WR work rate, ESWT 
endurance shuttle walk test, PFTs Pulmonary Function Test, SGRQ Saint George’s Respiratory Questionnaire, BDI/TDI baseline/transitional dyspnoea scores, MCID minimal 
clinically important difference. 
 
  
difficulties 
Dyer et 
al(189) 
a)COPD 
b)desaturation>
4% and below 
90% on ESWT 
c)>10% 
improvement in 
ESWT with AO. 
a)any form of 
Home Oxygen 
Parallel single 
blinded 
Oxygen 2-
6L/min 
Air 23 Air 
group, 24 
O2 group 
Supervised 7 
week exercise 
program-Twice 
weekly sessions 
a)ESWT b)CRQ 
c)HADS 
Improvement in ESWT 
in both groups 
compared to baseline 
p<0.0001.  
Improvement in ESWT 
in O2 group vs air group 
p<0.001 
Ringbaek 
et al(190) 
a)COPD; 
FEV1<80% 
predicted b)MRC 
3-5 
c)desaturation>
4% and below 
90% on 
ISWT/ESWT 
d)SpO2>90% at 
rest 
a)LTOT 
b)Significant 
musculoskeletal,
cardiac or 
cognitive 
problems 
Parallel un-blinded Oxygen 2l/min Air 22 O2 
group, 23 
air group 
20 week training 
program 
supervised for 
the first 7 weeks 
a)ESWT  
b)SGRQ  
Improvement in ESWT 
(time and distance) in 
both groups p<0.001 
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Author  Inclusion Exclusion Study type Intervention Comparator Sample Size Methods Outcome Results Summary 
M Soffer 
et al(191) 
COPD or restrictive 
ventilatory 
disease. 
SpO2<90% 
NR Non-RCT 
Cross over 
DODS CFNC 20 (13 
COPD) 
Treadmill 
exercise 
a)O2 
conservation 
ratio at 90% 
SpO2 
b)% O2 
savings 
DODs requires lower flow rate 
to achieve 90% saturations 
compared to CFNC. P<0.05 
(data from COPD patients 
alone) 
R Carter et 
al (192) 
COPD 
Exercise 
desaturation 
Resting SpO2 ≤90% 
NR Cross over DODs CFNC 10  Treadmill 
exercise test 
(1-1.5mpH) 
SpO2 on 
exercise 
DODs achieves statistically 
higher  SpO2 on exercise 
compared to CFNC p<0.001 
B Tiep et 
al(193) 
COPD No 
cardiovascular 
or orthopaedic 
limitations to 
exercise 
Non-RCT 
Cross over 
DODs CFNC 9  Treadmill 
exercise test 
O2 flow 
setting 
required to 
achieve 
SpO2>90% 
DODs requires lower flow rate 
to achieve 90% saturations 
p<0.0001 
Bower et 
al(194) 
Chronic lung 
disease 
Clinically stable 
NR Cross over DODS CFNC 5 COPD 
1 
COPD/scolio
sis 
Treadmill 
exercise test 
a)Oxygen 
usage 
percentage 
b)exercise 
SpO2 
 
No significant difference in 
exercise SpO2. 
DODS mean 02 utilisation is 
44% that of CFNC O2 
utilisation 
S. Braun et 
al (195) 
COPD: FEV1/FVC 
ratio <60%, 
LTOT 
NR Cross over DODS (5 
devices) 
CFNC 10 12minute 
walk test 
Average and 
lowest SpO2 
at rest and 
exertion  
No significant difference 
between the mean of the 
lowest SpO2 during exercise 
between intervention and 
comparator 
C Roberts 
et al (196) 
COPD 
Exercise 
desaturation <90% 
Clinically stable 
 
NR Cross over DODs CFNC 15 6MWT a)6MWT 
b)Time spent 
<90% SpO2 
CFNC significantly improved 
6MWD and reduced Time 
<90% SpO2 (compared to 
baseline) whereas DODs only 
improved 6MWT 
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A.Cuvelier 
et al(197) 
COPD-ATS criteria 
Clinically stable 
FEV1/FVC<65% 
FEV1<55% 
PaO2≤60mmHg at 
rest/PaO2>60mmH
g with evidence of 
exercise 
desaturation 
NR Cross over Refilled O2 
cylinders –
HomeFill 
system 
Standard 
commercial 
O2 cylinders 
10 Successive 
6MWT 
carrying 
standard 02 
and refilled 
02 cylinders 
a)6MWD 
b)mean SpO2 
at end of 
6MWT 
No significant difference 
between 6MWD orSpO2 
between cylinder types. 
B Tiep et 
al (198) 
Chronic lung 
disease 
Desaturation on 
exercise 
Clinically stable 
All patients using 
supplementary O2  
NR Non-RCT 
Crossover 
DODS CFNC 10 (9 COPD) Treadmill 
exercise 
test. O2 flow 
required to 
maintain 
saturations 
between 92 
and 94% 
O2 flow 
setting 
required to 
achieve 
SpO2>90% 
No significant difference in 
SpO2 at higher DODs setting. 
DODs confers 4.3 fold O2 
saving on exercise 
W.Chatila 
et al (199) 
COPD-GOLD 
criteria 
Clinically stable the 
preceding 3 
months 
Cardiovascular 
disease 
Non-RCT 
crossover 
Vapotherm 
(High flow 
oxygen 
20l/min) 
Low flow 
oxygen (2.5-
6l/min) 
10 (5 
completed 
exercise 
test) 
Cycling-
unloaded 
bicycle 
a)VT 
b)VE 
c)Work of 
Breathing 
d)Inspiratory 
time fraction  
d)RR/VT 
No significant difference in 
outcome measure (a,b or c) 
between Vapotherm or Low 
flow oxygen 
C Fuhrman 
et al (200) 
COPD FEV1<50 
%, PaO2<65mmHg. 
Current or former 
smoker 
No exacerbations 
in preceding 
3months  
Symptomatic 
cardiovascular 
disease. 
Any condition 
with 
contraindication 
to exercise 
testing 
Cross over DODs (4 
devices) 
CFNC 13 6MWT a)SpO2 at rest 
and exercise 
b)6MWT 
No significant difference in 
6MWD with any DODS device 
compared with CFNC 
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Table 3.2 Impact of device on Ambulatory oxygen delivery studies.DODs Demand oxygen devices, PRC Pendant reservoir cannulae, NR not reported, ATS American Thoracic 
Society, METS Metabolic equivalents 
S. 
Strickland 
et al (201) 
COPD-GOLD Stage 
4 
SpO2<90% 
LTOT 
Clinically stable 
preceding 6 weeks 
Symptomatic 
Cardiovascular 
disease 
Physical 
limitations 
precluding 
walking 
Cross over  a)Liquid O2 
system 
b)HomeFill 
compressed 
O2 system 
c)Portable O2 
concentrator 
Standard 
commercial 
O2 cylinders 
39 6MWT SpO2 on 
exercise 
No significant difference 
between SpO2 between 
interventions or comparator 
A Palwai 
et al (202) 
Obstructive lung 
disease, SpO2<90% 
at rest or on 
exertion. 
Hypoxaemia 
warranting use of 
supplementary O2. 
NR Cross over DODS (4 
devices) 
CFNC 13 Treadmill 
exercise test 
Modified 
Naugton 
protocol 
a)Work stages 
completed 
b)SpO2 
c)VE 
Significantly higher METs 
achieved with CFNC p=0.006 
 
Casaburi 
et al 
(203) 
COPD FEV1<60% 
PaO2<8kPa 
Clinically stable 
preceding month 
 
Uncontrolled 
heart failure. 
Orthopedic, 
neurological or 
cognitive 
limitations to 
exercise. 
Current 
smokers 
 
RCT 
Parallel 
Lightweight 
aluminium 
cylinders 
E cylinders 22 Unsupervise
d domestic 
activity 
Oxygen 
utilisation 
Home activity 
No significant difference in 
oxygen utilisation  or patterns 
of activity between 
lightweight and standard 
cylinder  
 
 
S Marti et 
al (204) 
COPD and ILD 
Exercise 
desaturation<88% 
Active smoker 
Use of AO 
therapy prior to 
study 
Recent 
exacerbation 
Crossover DODS/PRC CFNC 28 COPD 
31 ILD 
6MWT using 
intervention
/comparator 
a)% of 
patients with 
correction of 
exercise 
desaturation 
b)6MWD 
c)Borg scores 
Exercise desaturation 
corrected in 79% of patients 
with DODs and CFNC and in 
86% with PRC (data for COPD 
patients alone).  No significant 
difference between devices 
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Study Adequate 
Sequence 
generation 
Allocation 
Concealment 
Blinding Jadad Score 
Soffer 1985 Unclear Unclear No-high risk 2 
Carter 1986 Unclear Unclear No-high risk 2 
Bower 1988 Unclear Unclear No-high risk 2 
Braun 1992 Unclear Unclear No-high risk 2 
McDonald 1995 Unclear Unclear Yes-low risk 4 
Roberts 1996 Yes-low risk Yes-low risk No-high risk 3 
Rooyackers 1997 Yes-low risk Yes-low risk Unclear 2 
Tiep 1997 No-high risk No-high risk No-high risk 1 
Cuvelier 2002 Unclear Unclear No-high risk 2 
Eaton 2002 Unclear Unclear Yes-low risk 4 
Tiep 2002 No-high risk No-high risk No-high risk 1 
Emtner 2003 Yes-low risk Unclear Yes-low risk 5 
Chatila 2004 No-high risk No-high risk No-high risk 1 
Fuhrman 2004 Unclear Unclear No-high risk 2 
Nonoyama 2007 Unclear Unclear Yes-low risk 4 
Janaudis-Ferreira 2009 Yes-low risk Unclear Unclear 3 
Strickland 2009 Unclear Unclear No-high risk 2 
Palwai 2010 Unclear Unclear Yes-low risk 4 
Moore 2011 Yes-low risk Yes-low risk Yes-low risk 5 
Casaburi 2012 Yes-low risk Yes-low risk No-high risk 3 
Dyer 2012 Yes-low risk Yes-low risk No-high risk 3 
Marti 2013 Yes-low risk Yes-low risk Unclear 2 
Ringbaek 2013 Yes-low risk Yes-low risk Unclear 3 
 
Table 3.3:  Risk of bias in the included studies. 
 
 
 
 
 
79 
 
3.2 Clinical effectiveness of ambulatory oxygen 
 
3.2.0 Exercise Capacity 
 
4RCTs(182, 183, 187, 188) used 6MWT distance in assessing exercise capacity.  In the PR 
(pulmonary rehabilitation) studies(183, 187) the common effect (weighted mean 
difference) was 21.97metres in favour of the control group.  This result was mirrored in 
the meta-analysis of the domiciliary studies (182, 188); common effect 0.56 metres in 
favour of control.  However, neither result was statistically significant (95% CI -77.25 to 
33.32) and (95% CI -26.96 to 28.08) respectively, Figure 3.2.  2 PR RCTs(189, 190) used 
ESWT; they differed substantially in their results and therefore the pooled figure may be 
less meaningful. It was not statistically significant, common effect 150.02 seconds in 
favour of oxygen (95% CI -124.74 to 427.77 seconds, Figure 3.2).  2 PR RCTs(183, 185) 
used incremental work rate exercise testing via cycle ergometry to assess exercise 
capacity and found no difference with oxygen; 1.45 watts in favour of control (95% CI -
13.54 to 10.64 watts)), Figure 3.2).  2 PR RCTs(183, 185) measured constant power 
exercise tests using cycle ergometry.  There was a strong trend toward longer exercise 
time with oxygen (2.76 minutes longer (95% CI -0.07 to 5.58 minutes, Figure 3.2).   
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6MWT 
(domiciliary 
studies)
6MWT  
(metres)
ESWT (seconds)
Incremental 
power exercise 
(watts)
Constant work 
rate (mins)
 
Figure 3.2 Forest plots showing the effect of ambulatory oxygen therapy on exercise capacity. 
 
Two studies (both domiciliary) (184, 186) could not be used in the meta-analysis as one 
study provided p values only(184) and the other was the only one to use 5MWT(186).  
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Neither showed any statistical benefit of long term ambulatory oxygen on 6MWT distance 
(p=0.9) or 5MWT distance for individual participants. 
Borg dyspnoea Scores 
End of test Borg score were measured in 2 of the meta-analysed PR studies that used 
6MWT(182, 183, 187) and 2 RCTs using incremental work exercise testing(183, 185).  
Heterogeneity between the studies was not significant (I2=0%).  Neither were statistically 
significant; effect 0.16(-0.61 to 0.93) and 0.25(-0.81 to 1.31) respectively; Figure 3.3). 
 
Borg Score 6MWT 
Borg Score 
incremental 
power exercise
 
Figure 3.3 Forest plot showing the effect of ambulatory oxygen on end test exercise induced dyspnoea. 
 
3.2.1 Quality of life 
 
This was measured by CRQ (chronic respiratory questionnaire) in 7 studies(182-186, 188, 
189) 3 of which were PR studies.   In the PR studies there was no statistical difference 
between oxygen and control in any domain, however there was a strong trend to 
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statistical significance in CRQ emotion and fatigue favouring oxygen; p=0.06 and p=0.09 
respectively (Figure 3.4). In the domiciliary studies the effect in all domains was in favour 
of oxygen treatment, significant only in dyspnoea (p=0.002) and fatigue (p=0.01) (Figure 
3.5). 
CRQ Dyspnoea
CRQ Fatigue
CRQ Emotion
CRQ Mastery
 
 
Figure 3.4 Forest plots showing the results of ambulatory oxygen on HRQoL in the Pulmonary Rehab studies.
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CRQ Dyspnoea
CRQ Fatigue
CRQ Emotion
CRQ Mastery
 
Figure 3.5 Forest plots showing results of ambulatory oxygen on HRQoL in domiciliary studies. 
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3.3 Impact of device on ambulatory oxygen delivery 
 
14 studies evaluated a variety of oxygen conserving devices (OCDs) and cylinder 
types(191-204) (table 3). Modes of delivery included DODs (demand oxygen devices), PRC 
(Pendant reserve cannulae) and continuous flow nasal cannulae (CFNC).  In some studies 
multiple OCDs were compared.  Where this was the case, the most effective OCD was 
used in the meta-analysis comparing it to standard CFNC.   
5 OCDs studies(192, 194, 196, 200, 204)were used in two separate meta-analyses.  Tests 
for heterogeneity were not significant (both I2=0).   
3.3.0 Exercise capacity 
 
3 of the 5 meta-analysed studies compared DODS against standard CFNC using 6MWT as 
an outcome measure(196, 200, 204).   DODS and CFNC did not differ (CI-10.28 to 1.60), 
Figure 3.6).    
Exercise oxygen saturations 
Oxygen saturations were used in 2 of the 5 studies(192, 194) with methods of delivery 
being PRC and DODs respectively.  Oxygen saturations were 2.03% higher with OCDs 
compared to CFNC, (95% CI 0.09 to 3.98, p=0.04, Figure3.6). In contrast, Roberts et al 
demonstrated that DODs caused a significantly longer period of desaturation <90% than 
CFNC p<0.001.  
3.3.1 Oxygen utilisation 
 
Three studies(191, 193, 198) evaluated the ability of OCDs versus standard CFNC to 
conserve oxygen in patients during exercise by calculating an oxygen conservation ratio 
at 90% SpO2 (i.e. the relative difference in oxygen flow required to maintain oxygen 
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saturation with both devices at 90% SpO2).  2 studies used DODs(193, 198) and 1 
PRC(191). Although a higher DODS setting was required to maintain equivalent oxygen 
saturations, DODs still conferred 2.9-7.6 fold oxygen saving which was significant when 
compared to standard CFNC  p<0.001. A similar result was demonstrated with PRC; 
oxygen utilisation was significantly lower than CFNC p<0.05(191).  
3.3.2 Other outcomes 
 
Individual studies demonstrated no significant difference in exercise capacity with either 
refilled cylinders or portable oxygen concentrators when compared to standard 
commercial cylinders(197, 201).  Patterns of either home activity or oxygen utilisation 
were not significantly different when lightweight cylinders were used compared to 
heavier E cylinders.(203) 
6MWT
Exercise SpO2
 
Figure 3.6 Forest plot showing the effect of OCDs on exercise capacity and exercise saturations 
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3.4 Cost effectiveness 
 
There were no published studies found from the searches which assessed cost 
incremental ratios or cost effectiveness for ambulatory oxygen in addition to usual care. 
Since there were no studies that assessed this, and clinical effectiveness could not be 
proven in any domain, it was not possible to answer the question of whether ambulatory 
oxygen is cost-effective. However it may be relevant to consider what the potential cost 
of ambulatory oxygen would be if used widely in the UK. The prevalence of patients with 
COPD on 3 medicinal preparations (e.g. LABA/ICS,SABA and LAMA) and likely severe 
disease is 8.7%(2). Studies indicate the prevalence of EID in severe COPD at 
approximately 30%(80, 82). There are approximately 820,000(2) people with COPD in the 
UK and thus a conservative estimate of patients with EID in the UK is approximately 
21,000.  Previous studies have indicated variable ambulatory oxygen usage from  40-50 
minutes daily(182, 188) to 3.5 hrs(186). Using tariff data from Hertel et al(205) (daily unit 
cost £14.70) estimated annual costs would be £3.85 million if all patients were treated for 
40-50 minutes per day. This is a considerable burden to the health system, particularly if 
effectiveness is not well established. The results from the included studies imply that 
continuing to prescribe based on acute response which is reassessed in those who have 
completed pulmonary rehabilitation may be a way of limiting cost, and possibly treating 
those likely to benefit most at home. 
3.5 Discussion 
 
This review evaluated the use of ambulatory oxygen in three separate ways: efficacy 
against placebo, optimum mode of delivery and cost.  Firstly, we have shown that 
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ambulatory oxygen is unlikely to be effective at improving functional exercise capacity or 
symptoms of breathlessness in unselected patients with EID, although there may be some 
patients who respond well. Secondly we have shown that use of OCDs is appropriate, in 
that outcomes are similar or better to CFNC but at lower oxygen consumption. Since the 
review showed no significant overall effect of oxygen, and there were no published cost-
effectiveness studies we were unable to calculate an incremental cost effectiveness ratio 
(ICER). Each area of the results will be discussed here in turn. 
Clinical effectiveness of ambulatory oxygen 
The prescription of ambulatory oxygen therapy in COPD is governed by an improvement 
in exercise capacity or Borg dyspnoea scores, wherein a 10% improvement in distance 
walked or reduction ≥ 1 in Borg Score indicates it should be used in patients with EID> 
4%(78).  The majority of our results suggest that there is not a benefit of this magnitude 
(Figures 3.2 and 3.3). It is important to highlight that in the included studies the definition 
of EID was not uniform, ranging from mild (<92%) to more severe desaturation (<88%). 
Since results for some outcomes were heterogeneous it is important to consider how 
patient selection influenced results.  Two studies(182, 188)used exertional dyspnoea as 
their main inclusion criterion and were analysed separately, although 1/3 of patients in 
the Moore et al(188) study also exhibited EID.  Few studies specified “acute responders” 
(i.e. those with >10% improvement in walking distance);  The only study(189) which did 
used ESWT as the outcome measure and showed significant improvement in those 
randomised to ambulatory oxygen compared to compressed air, implying that 
appropriate patient selection is important in optimising clinical outcome. Interestingly 
however, 7 studies(182-186, 188, 190) included a single assessment acute oxygen test for 
all participants as part of their protocol.  All but one(190) demonstrated a significant 
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mean improvement in exercise capacity for participants with acute oxygen therapy 
compared to compressed air which is in line with a previous Cochrane review(100).  
Whether the acute effects of oxygen persist in the long term in trained or untrained 
participants was addressed in 2 of the included studies(183, 184) as they all included a 
repeat acute oxygen test at the end of the study period.  Rooyackers et al(183) and Eaton 
et al(184) both demonstrated that this acute effect was no longer statistically significant 
when using 6MWT as the outcome measure.  It would therefore seem that any acute 
improvement in walking distance observed in a single assessment study is not 
maintained.  This has implications for clinical practice as prescriptions for ambulatory 
oxygen based on improvements in exercise capacity observed in single assessment 
studies as suggested by guidelines(78) are not sustained or are minimal in the longer 
term. However, what currently determines the longer term efficacy of AOT is the 
subjective assessment of whether patients feel it has helped them increase their own 
physical activity.  Where patients feel there has been no benefit; AOT is removed.  
The way in which exercise capacity was measured may also be relevant to the 
interpretation of results. Largely it was measured using field tests (ESWT or 6MWT) which 
particularly in the case of the 6MWT have been suggested to relate more to activities of 
daily living(96, 206).  The meta-analysis of exercise capacity with respect to 6MWT 
slightly favoured the control group and showed no benefit of ambulatory oxygen, 
implying that in normal daily life it would not be expected to help patients be more 
active.  In the ESWT meta-analysis, although the result was not statistically significant in 
favour of oxygen therapy it may be clinically significant.  The MCID for the ESWT is 
estimated at 45-85 seconds (207).  The common effect of 150 seconds exceeded this 
although this must be approached with caution because the heterogeneity between the 
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two studies(189, 190)was considerable.  Both enrolled patients exhibiting EID>4% and 
predominantly severe COPD. During the ESWT in the Dyer et al (189)study patients had 
their oxygen cylinders carried by an assistant whereas this was not the case in Ringbaek 
et al(190).  It is recognised that any improvement in exercise capacity can be negated by 
the weight of the ambulatory oxygen system if carried by patients alone(196, 208), thus it 
is possible the Dyer study overinflated the benefits of treatment in real life by providing 
assistance.  The meta-analysis of endurance cycle time strongly favoured oxygen 
treatment and was close to approaching statistical significance. Furthermore this is likely 
to be an underestimate of the effect of ambulatory oxygen treatment as 16 endurance 
tests in the oxygen group were terminated at 30mins compared to 6 endurance tests in 
the control group(185). The responsiveness of constant work rate test such as the ESWT 
and cycle endurance to intervention is far better than 6MWT(209) which may explain the 
discrepancy between these different exercise outcome results. However at present no 
MCID for cycle ergometry has been established and its relationship to activities of daily 
living is unclear.  Thus far no study of ambulatory oxygen therapy has used home activity 
or activities of daily living as an outcome measure.  Real world performance of 
ambulatory oxygen has been largely gauged by 6MWT results.  It is now possible to 
measure home activity with a number of validated accelerometers(180).  This was part of 
the rationale for including home activity as an outcome measure in the Ambulatory 
oxygen study for muscles in COPD trial (NCT01722370) which forms chapter 4 of this 
thesis.  Given that 6MWT is also an outcome measure we will be able to explore the 
relationship between them. 
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Some studies(183, 185, 187, 189, 190) were carried out as part of pulmonary 
rehabilitation.  Although no statistical benefit of long term ambulatory oxygen was 
demonstrated, exercise capacity (particularly 6MWT) in the pulmonary rehabilitation 
studies exceeded that of the domiciliary studies(182, 188)whether patients were 
randomised to ambulatory oxygen or placebo, figure 2.1 and 2.2.  What is also clear is the 
improvement in 6MWT distance gained by pulmonary rehabilitation far exceeds that 
gained by ambulatory oxygen(183).  This supports current guidelines(78) in that any 
assessment of ambulatory oxygen therapy should be made following pulmonary 
rehabilitation. 
Finally, it is important to consider the meta-analyses possible using CRQ domains. In 
general there was a benefit of ambulatory oxygen on QoL, which was most pronounced in 
the dyspnoea and fatigue domains; the others were not statistically significant but 
showed a strong trend in the same direction. However, the effect size was only 0.28 and 
0.17 in the statistically significant domains.  Although the MCID for PR adjuncts has not 
been established it is less than the proposed 0.5 points which is considered to represent 
the MCID for an individual CRQ domain(210). This explains the apparent discrepancy 
between Borg score and CRQ dyspnoea score meta-analyses; neither were clinically 
significant, thus they concur, despite the fact that statistically the CRQ score was better 
with oxygen. The effect size is also considerably less than the effect on CRQ of pulmonary 
rehabilitation (0.62 points) (211) confirming that assessment for ambulatory oxygen 
should only be done after rehabilitation.  
Impact of device on ambulatory oxygen delivery 
The mode of delivery of ambulatory oxygen therapy largely encompasses the cylinder 
type and the interface used.  Oxygen conserving devices (DODS/PRC) have been used for 
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many years and the theory supporting their use has been discussed elsewhere (193).  In 
short “classic” DODs devices deliver oxygen during the initial phase of inspiration alone 
whilst PRC stores oxygen during exhalation to be delivered at the next inspiratory phase.  
The role of OCDs is to conserve oxygen however in doing so must perform equivalently to 
standard CFNC in ameliorating oxygen desaturation.  Some studies(192, 194, 196, 200, 
204) included in the meta-analysis indicate that oxygen conserving devices perform 
equivalently to standard CFNC at maintaining exercise oxygen saturation and 6MWT.  
Importantly however, it is likely that oxygen conserving devices achieves these outcomes 
at a much lower oxygen utilisation than CFNC.  This is likely to have implications in terms 
of oxygen cylinder usage and subsequent cost. Although the primary role of OCDs is not 
to improve exercise performance over CFNC, patients use these devices on the premise 
that they are ambulatory.  Thus it is reassuring that functional performance is not 
negated by the weight of the system.  
 It is important to note that there was considerable variation between OCDs and their 
performance and in the meta-analyses the best performing OCD was used.   Notably in 
the study by Palwai et al (202) one of the DODs systems performed no better than 
ambulation on room air. Also there may be some patients that do not tolerate OCDs and 
their use may cause further desaturation.  This is supported by the study by Marti et al 
(204)  in which use of DODs failed to correct EID in approximately a fifth of participants. 
This has been explained by a change in respiratory pattern on more strenuous exertion 
where by the predominance of mouth breathing rather than nasal a fails to trigger the 
flow sensor(196). 
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Oxygen cylinders have historically been the main method of delivering portable oxygen, 
however newer devices such as portable concentrators are now available.  These devices 
have variable weight with cylinders weighing between 3.4-8kg and portable 
concentrators between 3-4kg. As mentioned previously the weight of the ambulatory 
oxygen system (cylinder in this case) is important factor as the portable oxygen system 
should be carried by the patient during their ambulatory oxygen assessment and 
following this in their ambulatory activity. The weight of the portable oxygen systems has 
previously been cited as one of the reasons why patients with COPD have poor 
concordance with ambulatory oxygen prescriptions(212). An interesting observation from 
one of the studies (203) is that ambulatory cylinder weight had no impact on home 
activity.  One would hypothesize that a lower weight would facilitate ambulation. This 
was not the case despite prior efforts of focused education on increasing oxygen 
treatment understanding and ambulation.    
The comparison of standard cylinders (197) to refillable (Homefill), portable 
concentrators and lightweight cylinders demonstrated no difference in exercise capacity 
(6MWT), oxygen saturations or time used.  From this one can conclude that most 
portable oxygen systems perform equivalently and when used should be coupled with 
oxygen conserving devices in the first instance.  Currently when ordering ambulatory 
oxygen, the HOOF (Home oxygen order form) system tends to select OCD devices for 
those who are most active which is in line with current evidence(81). 
There are a number of limitations to the meta-analysed data in this chapter.  The quality 
of data in from the published papers was poor to average limited by small sample sizes 
and high risk of selection and detection bias especially in the older studies.  In addition, 
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patient selection and heterogeneity of outcomes may limit the generalisability of the 
results. There were no published studies on cost effectiveness of AOT.  Whilst cost 
effectiveness has been evaluated to some extent in inhaled therapies in COPD the lack of 
data in this area with respect to AOT may be due to the difficulty analysing specific 
outcomes.  Inhaled therapies have been shown to reduce exacerbations rates; mild to 
severe and consequently in many cases healthcare utilisation. These outcomes can be 
defined by cost, especially in the context of hospital admissions where which 
exacerbations are grouped under a Healthcare Resource Group (HRG) with an indicated 
cost(205).  AOT main effect is to increase functional exercise capacity and negate 
desaturation.  Whilst AOT will have an effect on QoL and exercise capacity it is difficult to 
define the economical impact of these benefits.  Finally as alluded to in this section, 
outcomes in this chapter did not include other clinically relevant endpoints such as 
exacerbations or mortality largely due to paucity of information. 
Conclusion 
 
Although limited by patient selection and heterogeneity in outcomes this review has 
shown that in unselected patients with EID AOT is unlikely to provide lasting clinically 
meaningful improvements in exercise capacity, when judged by the 6mwt or in BORG 
scores. However, some patients may respond well and derive benefit either clinically or 
subjectively.  Pulmonary rehabilitation should be undertaken before AOT assessment as 
the improvement in exercise capacity from PR far exceeds any improvement when 
standalone oxygen is given to patients in a domiciliary setting.  When AOT is prescribed, 
OCDs should be use in preference to CFNC as they are likely to achieve similar oxygen 
saturations and mitigate oxygen desaturation at lower total oxygen usage.    
94 
 
Several studies in this review where in the setting of pulmonary rehabilitation, which 
have been shown to improve exercise outcomes(213) with the resistance component  
improving markers of muscle myogenesis(214).  Domiciliary studies whether supported 
by AOT have never used skeletal muscle myogenesis or gene expression as an outcome 
measure.  Since there is no exercise component in these studies; benefits in exercise or 
skeletal muscle outcomes must either be derived from a direct action of oxygen or 
improvements in physical activity; one of the assumptions made when AOT is prescribed.  
Moreover, no study included in this review measured physical activity directly by use of 
activity monitors or using patient reported questionnaires of activity during the study 
period.  Therefore, it is unclear what affect AOT would have on patient physical activity 
and whether this translates to improved exercise or skeletal muscle outcomes.  This is the 
subject of investigation in chapter 4. 
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Chapter 4 
Clinical Outcomes 
 
This chapter outlines the clinical results from the Ambulatory oxygen for muscles in COPD 
trial (NCT01722370); the methods for which are discussed in chapter 2.2.  This study 
investigated the role of AOT on skeletal muscle gene expression, systemic inflammation, 
physical activity, exercise capacity and quality of life. 
Patients were recruited between September 2012 and August 2014 and randomised to 
12 weeks of AOT or placebo air in a cross over fashion.  Skeletal muscle biopsies were 
taken at trial enrolment (baseline sample) and after each intervention.  Markers of 
systemic inflammation and exercise capacity were measured at the same timepoints as 
above. In addition to measuring physical activity at trial enrolment and after each 
intervention, physical activity was also measured at the midpoint of each intervention, 
i.e. at 6 weeks.  The study design diagram is shown in figure 4.0 
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Screening visit 
Spirometry, 6MWT
Enrolment visit 1 (week 1) Start of trial
Consent, allocation by SNOSE
QOL, HADS, blood gas, venous blood
Data collection for COPD phenotypes
Muscle biopsy
Blood collection before 
Pre trial activity monitor issued
Visit 2 (1 week after visit 1): Collection of activity monitors 
IMP/placebo dispensing
Visit 3 (6 weeks after 
starting IMP/placebo):
QOL
Activity monitor issued
Visit 4 (12 weeks; end of 
IMP/placebo)
Spirometry, 6MWT
QOL, HADS, blood gas, venous blood
Data collection for COPD phenotypes
Muscle biopsy
Bloods as before
Activity monitor issued
1-2 
week 
break 
then 
dispens
ing of 
new 
product
Visit 5 (6 weeks after starting 
IMP/placebo)
QOL
Activity monitor issued
Visit 6 (12 weeks after starting 
IMP/placebo)
Spirometry, 6MWT
QOL, HADS, blood gas, venous blood
Data collection for COPD phenotypes
Muscle biopsy
Bloods as before
Activity monitor issued
Follow up visit  (6 weeks after 
IMP/placebo end)
Post trial activity monitor issued
Collect monitor
QOL, HADS
Spirometry
 
Figure 4.0: Study design Diagram 
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4.1 Patient characteristics 
 
Twenty five participants were recruited to the clinical trial following the initial screening 
of thirty two patients.  All participants had completed pulmonary rehabilitation within 2 
years prior to trial enrolment and demonstrated exercise induced desaturation to a nadir 
<88%.  All but one patient had obstructive lung disease with a FEV1/FVC ratio of <70% 
with the remaining patient having radiological upper zone predominant emphysema. 
Seventeen patients completed the trial.  The reasons for non-completion were that 1 
patient required LTOT, 3 were lost to follow up and 4 withdrew consent.  The trial study 
plan is shown in figure 4.1. 
Assessed for eligibility n=32
Randomised n=25
Excluded n=7
4 declined
3 no evidence of 
desaturation
Ambulatory oxygen
N=10
Air N=7
Ambulatory oxygen
N=7 Air N=10
N=4 withdrawal of consent
N= 1 lost to follow up
N=2 lost to follow up
N=1 required LTOT
Follow up Follow up
Period 1
Period 2
 
Figure 4.1: Trial flow diagram 
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In general the recruited patients had spirometrically severe COPD, were very 
symptomatic and had anxiety/depression scores indicative of clinically significant 
psychological co-morbidity. There was considerable variability in baseline exercise 
capacity, as demonstrated by the 6 minute walk test distance and there was a wide range 
of body mass indices (BMI).  Table 4.1 shows the baseline demographic and clinical data. 
        
 
 
 
 
 
 
 
 
 
Table 4.1: Baseline demographic data for trial participants. Data expressed as mean (Standard deviation), 
Median(25th-75th Quartile) 
4.2 Cylinder usage 
 
Cylinders weighed approximately 4kg.  Oxygen flow rates were set at 2l/min and patients 
were instructed to use this flow rate when performing routine physical activity. The mean 
number of cylinders used during oxygen treatment was 5 (1.62) compared to 4.82(2.21) 
Age (years) 67.35(7.45) 
Gender (M:F) 7:10 
FEV1 absolute (litres) 
FEV1% predicted 
1.18(0.7) 
50(23.6) 
FVC absolute (litres) 
FVC % predicted 
2.27(0.72) 
80.5(18.87) 
Desaturation nadir % 86(85-88) 
BMI (kg/m2 ) 28.77(19.2-30.07) 
Baseline 6MWT distance (metres) 223(143.9) 
Baseline CAT score 27.94(6.45) 
Baseline HAD Score 17.17(5.97) 
Baseline home activity (VMU/min) 251.3(157.3-430.07) 
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during the air treatment phase (p=0.78).   The cylinders provided by BOC had a run time 
of approximately 5hrs at 2l/min.  Given the mean cylinder usage, this would equate to 
less than one hour; approximately 30mins air/oxygen use daily. 
 
4.3 Exercise capacity and Home Activity 
 
At baseline 6MWT distance correlated significantly with baseline lung function (FEV1%) 
(r=0.63, p=0.007, figure 4.3) but no other clinical variable.  6MWT distance was not 
significantly different in patients with high (BMI>25) or low (BMI<25) p=0.399.  The 
extent of exertional desaturation did not correlate with 6MWT distance during air or 
oxygen treatment (Spearman’s R=-0.001, p=0.97 and Spearman’s R=0.11, p=0.68) 
respectively. 
 
 
 
Figure 4.2: Correlation of baseline 6MWT and FEV1% predicted r=0.63 p=0.007 
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Exercise capacity (6MWT) increased from baseline in both arms of treatment. The 
magnitude of improvement was greater during ambulatory oxygen treatment 
(34.06metres compared to 16.25 metres).  However, neither of these improvements from 
baseline was statistically significant p=0.279 and p=0.51 for ambulatory oxygen and air 
treatments respectively.  Use of the tri-axial accelerometer showed that patients were 
generally inactive with no patient spending more than 10% of the time in moderate to 
vigorous physical activity at any point during the trial.  Home activity improved from 
baseline during AOT both at trial midpoint and at trial end.  Neither of these changes 
were statistically significant.  Midpoint home activity was not significantly different to 
home activity at the end of the treatment phase during AOT or air treatment; p=0.91 and 
p=0.86 respectively.  Table 4.2 summarises these results. 
 Air Oxygen Air vs 
Baseline 
Oxygen vs 
Baseline 
Air vs 
Oxygen 
6MWT 16.25m (99.25) 34.06m 
(125.33) 
P=0.51 P=0.279 P=0.65 
Home Activity 
At Trial 
midpoint 
241.75(169.7-
376.8) 
279(207.3-
415.86) 
P=0.99 P=0.37 P=0.41 
Home activity 
Trial end 
(VMU/min) 
238.3(171.3-
374.38) 
278.9 (207.4-
413.43) 
P=0.875 P=0.308 P=0.32 
 
Table 4.2: Table shows the change from baseline in 6MWT distance following interventions and 
home activity (VMU/min) at the end of each intervention period. 
 
Interestingly home activity following oxygen treatment correlated significantly with 
6MWT following ambulatory oxygen treatment (Spearman’s R=0.751, p=0.005). This 
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relationship however was not present at baseline (Spearman’s R=0.399, p=0.199) or 
following air treatment (Spearman’s R=0.441, p=0.152, figure 4.3a-c). 
 
a) Spearman’s R=0.399, p=0.199 b) Spearman’s R=0.441, p=0.152 c) Spearman’s R=0.751, p=0.005
Figure 4.3 a-c) Correlation of home activity with 6MWT distance at baseline, following air (Treatment A) and 
ambulatory oxygen (Treatment B)
 
4.4 Health related quality of life and Anxiety and Depression 
 
All recruited patients had baseline CAT scores of more than 20 indicating that COPD had a 
clinically significant impact on their quality of life.   As with exercise capacity the response 
to treatment was heterogeneous.  Following oxygen treatment 11/17 patients had 
reduced (improved symptom) scores compared to 8/17 following air treatment.  The 
mean change from baseline was -1.59(6.86) following oxygen treatment and 0.64(4.24) 
following air.  Neither were statistically significant (p=0.354 and p=0.538 respectively). 
All but one patient at baseline had evidence of clinically significant anxiety and 
depression.  Following both interventions there was a reduction (improved symptoms) in 
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HADs score; -2.47(4.45) with oxygen treatment and -1.82(4.57).  Table 4.3 summarises 
these results. 
 Air Oxygen Air vs 
Baseline 
Oxygen vs 
Baseline 
Air vs 
Oxygen 
CAT 0.64(4.24) -1.59(6.86) P=0.35 P=0.54 P=0.26 
HADs -2.47(4.45) -1.82(4.57) P=0.13 P=0.04 P=0.79 
 
Table 4.3: Change from baseline scores for HADs and CAT. 
Only the improvement in HADs from baseline following oxygen treatment reached 
statistically significance; p=0.04 compared to p=0.13 following air treatment, however 
there was no significant difference between AOT and air treatment. Figure 4.4 shows the 
individual HADs patient scores during treatment phases. 
 
 
Figure 4.4: HADs score during treatment arms 
4.5 Systemic Inflammation 
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The results of the plasma cytokine levels in response to oxygen and air treatment are 
shown in table 4.4.  TNF alpha levels were generally low and did not show significant 
change following either intervention. 
 
 Baseline Air Oxygen Air vs 
Baseline 
Oxygen 
vs 
Baseline 
Air vs 
Oxygen 
Il-6 
pg/ml 
19.01(10.88-
63.47) 
28.61(10.52-
62.72) 
12.17(7.82-
41.91) 
P=0.94 P=0.04 P=0.35 
Il-8 
pg/ml 
5.29(4.35-
7.33) 
6.33(5.08-8.03) 5.57(4.44-6.64) P=0.48 P=0.58 P=0.89 
IFN-g 
pg/ml 
181.25(99.73-
273.84) 
215.06(132.37-
372.07) 
267.92(123.73-
285.87 
P=0.31 P=0.35 P=0.76 
TNF-α 
pg/ml 
0.57(0.45-
0.81) 
0.54(0.48-1.13) 0.48(0.4-1.05) P=0.53 P=0.37 P=0.92 
 
Table 4.4: Systemic cytokine response to oxygen and air during clinical trial. 
Plasma interferon gamma levels rose following both treatments but this change was not 
significantly different from baseline.  The only significant change from baseline during the 
clinical study was a reduction in plasma IL-6 levels following oxygen treatment although 
there was between group difference was not significant. Individual patient responses of 
IL-6 and treatment are shown in figure 4.5 
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Figure 4.5: Plasma IL-6 during treatment arms 
 
4.6 Discussion 
 
The secondary aims of this study were to determine whether ambulatory oxygen therapy 
had any long term impact on functional exercise capacity, quality of life or systemic 
inflammation. The results from the systematic review analysis (chapter 3) suggest that it 
would have little impact on these clinical outcomes save for quality of life.  The benefits 
of this study in comparison to others presented in chapter 3 are that the duration of the 
study is far longer than any previous study which assessed ambulatory oxygen in a 
domiciliary setting. It also investigated, systemic inflammatory response and home 
activity alongside functional exercise capacity, as measured by the 6MWT.  The 
hypothesised mechanisms by which AOT may mitigate EID and improve exercise capacity 
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have been discussed in 1.4.1 and 1.5.1. Briefly they include, improved V/Q ratios and 
arterial oxygen concentration, reduction in peripheral chemoreceptor activity, reduction 
in peripheral/central fatigue and reduction in skeletal muscle lactic acid production. 
Collectively these mechanisms are likely to result in either improved arterial oxygenation 
or reduction in the sensation of dyspnoea which may both beneficially effect exercise 
capacity or activity.  Central to this therein is the use of AOT.  During the trial cylinder 
usage both for AOT and air was low; roughly equating to less than 30mins daily use.  It is 
unlikely therefore that usage was sufficient to mediate either direct action of oxygen or 
that AOT encouraged participants in the trial to be more active. The effects of AOT on 
functional exercise capacity and home activity are discussed in turn.  
Functional exercise capacity has been shown to be reduced in COPD patients(215) with a 
number of factors determining poor 6MWT performance (defined as a 6MWT distance 
<350metres)(216). Determinants of 6MWT distance are complex, however airflow 
limitation and the presence of depressive symptoms are two variables which have been 
shown to influence it(216).  The significant positive correlation between FEV1 % predicted 
and 6MWT in the data figure 4.3 supports this although at best only explains 39% of the 
variance in baseline 6MWT in the cohort of patients enrolled.  Low BMI has been also 
linked to poor 6MWT performance(217). However in this cohort 6MWT distance at 
baseline did not differ when the cohort was dichotomised too high and low BMI.  This in 
part may be due to the small numbers of patients in the study.  Also, it is acknowledged 
that BMI is a poor surrogate for fat free mass which is linked to sarcopenia and reduced 
exercise capacity(218).  The improvement in 6MWT distance compared to baseline 
following AOT was almost double that of air and greater than that shown in other 
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domiciliary studies (182, 188). This improvement although not statistically significant it is 
important to explore if it has any clinical relevance. Evidence from the ECLIPSE 
(Evaluation of COPD Longitudinally to Identify Predictive Surrogate End Points) cohort 
suggests that the MCID (minimum clinically important difference) for 6MWT is 30metres 
and represents increased risk of death from exacerbations(219). Since some patients 
enrolled in the study improved by more than the MCID and the study population was 
smaller than intended at the outset, thus could be underpowered, it would be 
worthwhile to conduct a larger study to determine if the improvement is genuine or not.  
Domestic activity is also reduced in patients with COPD.  The results from the clinical 
study suggest that baseline activity in the enrolled participants was relatively low (median 
238.3 VMU/min) with very little time spent doing moderate or vigorous activity.  This is 
consistent with prior observational work in our local population(220) gathered as 
preliminary data prior to this trial.  This study showed the patients with COPD spent a 
greater proportion of time sedentary and far less doing moderate to vigorous physical 
activity.  A VMU of 290/min roughly equates to a walking speed on a treadmill of 
1mph(221), which is significantly slower than in health (~4 mph).  The reduced activity 
levels in the enrolled patients are consistent with a number of other studies (203, 220).   
The study by Casburi et al (203) demonstrated physical activity was low VMU 108.9 (48.6) 
albeit in patients receiving LTOT therapy.   
Domestic activity improved following oxygen treatment although this was not statistically 
significant.  The trend to improved domestic activity with oxygen therapy was also 
demonstrated in a study by Sandland et al (166) which included heterogeneous COPD 
population of patients with EID (nadir ≤ 90%) and those on LTOT.  Interestingly there was 
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not a significant change in home activity at the trial midpoints i.e. when participants were 
using either intervention.  This again indicates that AOT usage did not encourage 
increased activity in this cohort of participants.  At present no MCID for data derived from 
accelerometers has been established so the clinical relevance of the improved activity 
with oxygen in not clear.  Interestingly however the correlation between home activity 
and 6MWT during oxygen treatment was strongly significant (Spearman’s Rho 0.751 
p=0.005); a relationship that was not present at baseline nor following air treatment.  
This indicates firstly that the two variables correlate well, which one of the cited benefits 
of the 6MWT and secondly that the improvement in 6MWT with ambulatory oxygen is 
likely to be relevant as it may also have a clinically meaningful translation to home day to 
day activity.   
In the future the measurement of physical activity in patients with COPD is likely to 
involve the use of structured questionnaires.  Whilst accelerometers such as Actigraph 
have been well validated in this group of patients the ability of these devices to capture 
patients’ experience/perceptions of activity is doubtful.  Patients often limit physical 
activity to avoid symptoms(222) and may find themselves modifying their lifestyle 
because of this.  This important information would not be gleaned from an accelerometer 
alone and has led to the formation of two questionnaires; daily proactive physical activity 
in COPD and clinical proactive physical activity in COPD which have shown promise in 
terms of their validity and reliability.   
Health related quality of life (HRQoL) and anxiety and depression were assessed using the 
CAT and HADs scores.  The CAT and HADs are measured out of 40 and 28 respectively 
with higher scores indicating worse symptoms.  There was a trend to improved scores 
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following ambulatory oxygen therapy, significant only for HADs. The CAT assessment has 
not been previously used in studies of domiciliary ambulatory oxygen therapy.  Previous 
studies used CRQ(182, 184, 188) which encompass 4 domains; fatigue, dyspnoea, 
emotion and mastery.  The results from the systematic review in chapter 3 show use of 
ambulatory oxygen in a domiciliary setting significantly improved dyspnoea and fatigue 
alone; p=0.002 and p=0.01 respectively.  Although these were significant improvements 
neither were clinically relevant; both effect sizes falling below the MCID.  The trend to 
improvement in CAT score in this study concurs with the above and not likely to be 
clinically relevant given the MCID estimated for CAT is 2 points(223).  
This study suggests that ambulatory oxygen therapy has a greater effect on anxiety and 
depression compared to the functional impact of COPD symptoms. Anxiety and 
depression are common co-morbidities In COPD with prevalence ranging between 13-
46%(224).  Both are likely to adversely affect quality of life and treatment adherence(225) 
and as alluded to earlier depressive symptoms also detrimentally affect functional 
performance i.e. 6MWT.  The management is multifaceted and involves use of anti-
depressants, cognitive behavioural therapy and pulmonary rehabilitation.  Here we show 
use of ambulatory oxygen influences anxiety and depression; significantly improved HADs 
score following treatment.  Although there is no direct comparison, CRQ mastery and 
emotion scores which cover similar themes to HADs have shown a trend to improvement 
with oxygen use in studies of ambulatory oxygen therapy(182, 184) which supports this. 
Of note the HADs score also improved following air treatment.  It is well recognised that 
many patient enrolled into clinical trials have improved quality of life even if randomised 
to placebo.  This is in part due to the regular review visits patients undertake during a 
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clinical trial; in this case 6.  However the role of “placebo” air is likely be important.  The 
patient perception of oxygen in COPD is complex.  Many patients see the use of oxygen 
therapy as a milestone of disease progression and are keen to avoid its use(226).  
Contrary to this the perception of oxygen therapy for some is that of a treatment which 
will improve dyspnoea, fatigue or help them do more(227).  The perception that 
dyspnoea and hypoxia are interlinked and remedied solely by oxygen therapy seems to 
be a common view for some patients with COPD.  From experience there is an intrinsic 
attachment to oxygen therapy when it is prescribed and there is some degree of anxiety 
if patients are told they no longer need it.  It is highly plausible that placebo air would be 
more prone to this placebo effect given the above. 
Systemic inflammation is thought to be a key component in COPD and implicated in the 
aetiology of SKMD as discussed in chapter 1.  The cytokines measured in the study 
showed a differential response to ambulatory oxygen treatment.  Plasma IL-6 and to 
some degree TNF α were reduced compared to baseline following oxygen treatment, 
with the reduction in plasma IL-6 reaching statistical significance although there was not 
a between group difference. Both TNF α and IL-6 are pro-inflammatory cytokines, 
recognised to be altered in COPD(228). TNF α signalling is mediated through two cell 
surface receptors (TNFR1 and TNFR2) whilst IL-6 classically via the IL-6 receptor(229-231).  
Both have been shown to activate the Nf-kB (nuclear factor Kappa B), which under 
normal conditions is present within the cytoplasm in an inactive state, bound to an 
inhibitory protein. Stimulation via either TNF α or IL-6 leads to an intracellular signalling 
cascade resulting IKK (inhibitor of kB kinase) phosphorylation of the Nf-kB/inhibitor 
complex which releases Nf-kB to the nucleus of the cell.  Here, Nf-kB co-ordinates the 
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transcription of a number of chemokines, cytokines and ubiquitin proteasome pathway 
(UbP) leading to muscle atrophy(229).   TNF α and IL-6 have been shown to cause muscle 
atrophy and impair myogenic differentiation in murine and in vitro studies(232, 233).  
Elevated levels of IL-6 have also been associated with radiological evidence of quadriceps 
wasting in COPD patients(141). 
In contrast plasma IL-8 and IFN-g levels rose compared to baseline following oxygen 
treatment. The role of IFN-g in skeletal muscle signalling is not completely understood.  
Some studies have demonstrated that IFN-g is required for efficient skeletal muscle 
regeneration (234, 235).   However in a murine model over expression of IFN-g at the 
neuromuscular junction caused a necrotizing myopathy (236).  Muscle repair and 
differentiation occurs following a number of stimuli including exercise and is likely to 
have occurred during the trial period following episodes of exertion in the participant 
cohort. One would hypothesize that the elevated levels from baseline in both treatments 
(although not significant) represents this. IL-8 levels have been inversely correlated with 
quadriceps muscle strength albeit during exacerbations of COPD (140) and may also 
activate the NF kB pathway in the same way as TNF α and IL-6.  Although plasma levels 
IL8 rose during oxygen treatment, the rise was not significant.    
There are a number of limitations to these results.  Practice walks where not undertaken 
during the 6MWT. The standards for performing the 6MWT were published after patients 
were enrolled into the clinical trial. It is recognised that there is a learning effect when 
undertaking the 6MWT and this may have over inflated the benefits of oxygen therapy.  
Cylinder usage was low although mean usage however between the two treatments did 
not differ. This is consistent with previous data from local COPD patients showing that 
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activity levels were low(220), such that we feel the low usage of cylinders represents a 
true reflection of activity levels.  The clinical trial was double blinded with cylinder flow 
rates were regulated at 2l/min. We accept that this may not have ameliorate EID in all 
participants.  The cytokines measured were from the systemic circulation; changes in the 
systemic circulation may not directly represent those which occur at the muscle level and 
there is some evidence to suggest that this may be negligible (237). It is also likely the 
study was underpowered to detect differences in the clinical outcomes measured. 
Assessment of quadriceps strength is a notable omission from the study outcomes.  This 
would have aided in the phenotyping of patients with skeletal muscle dysfunction and 
not just those with reduced exercise capacity.  However we were limited in this by lack of 
the equipment to do this at our hospital enrolment and clinical site.  
 
Conclusion 
 
Ambulatory oxygen therapy use in patients with exertional hypoxaemia did not 
significantly alter functional exercise capacity, home physical activity which is low in this 
population of patients or quality of life.  The reduction in plasma IL-6 from baseline would 
need to be investigated further however in this cohort of patients AOT did not reduce 
systemic inflammation. The low cylinder usage during the trial is likely a key mediating 
factor in all of these outcomes. 
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Chapter 5 
Gene expression response to Ambulatory Oxygen and Air 
This chapter outlines the gene expression results for the Ambulatory oxygen for muscles 
in COPD trial; the general and statistical methods of which are discussed in chapter 2. The 
results from chapter 4 suggest that AOT may have little effect on skeletal muscle gene 
expression given the lack of effect on clinical outcomes.  Skeletal muscle biopsies were 
taken at trial enrolment (trial diagram, page 96) and at the end of each intervention with 
muscle biopsies undergoing transcriptomic analysis to explore differentially expressed 
genes during AOT and air treatment.  Microarrays rather than target gene or protein 
analysis were used as it lends itself more to exploratory analysis when evaluating high 
through put gene expression changes.  Differential gene expression was undertaken using 
the R Bioconductor platform. The microarrays experimental design was two channel 
meaning that each baseline sample of muscle was hybridised with an intervention sample 
i.e. baseline sample with sample following AOT.  Using this design enabled a direct 
comparison of air vs AOT. 
5.1 Demographic Data 
Eight patients underwent muscle biopsy at all three time points; at baseline and following 
air or oxygen interventions.  The remainder of the patients refused further biopsies 
stating pain or difficulty with ambulation as the main reasons.  They were therefore 
excluded from the microarray data analyses. 
The demographic data for the patients included in the gene expression analyses is shown 
in table 5.1 
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Age (years 
Sex (M:F) 
FEV1% 
Baseline 6MWT (metres) 
BMI (kg/m2 ) 
O2 saturations at baseline (%) 
Nadir O2 saturations during 6MWT 
pH 
pCO2 (kPa) 
pO2 (kPa) 
HCO3 (mmol) 
CAT 
HAD 
Activity (VMU/min) 
TNFα pg/ml 
IL-6 pg/ml 
IL-8 pg/ml 
IFGγ pg/ml 
67.13 (8.74) 
5:3 
48.88 (26.2) 
226.88(158.2) 
29.72(18.54-31.10) 
93(1.4) 
84.6(4.0) 
7.4(0.01) 
5.5(0.45) 
8.36(0.89) 
25.3(1.57) 
29.5 (5.5) 
18.75(5) 
226.18(65.4) 
0.55(0.17) 
29.93(22.1) 
6.25(3.7) 
187.5(77.8) 
 
Mean (SD), median (25th -75th Centile) 
Table 5.1: Demographic data for patients included in gene expression data analysis. 
 
5.2 Microarray Quality Assessment 
Array data quality can be affected during the experimental process. When analysing 
arrays together the quality of each individual array needs to be assessed. The quality of 
microarray data was assessed using the “arrayQualityMetrics”(238) in Bioconductor 
114 
 
R(239).  This package enables each individual microarray to be evaluated separately and 
in conjunction with the other microarrays to detect arrays where which the data quality 
may have been subject to errors during the experimental process, e.g. hybridisation or 
dye labelling.  This can take the form of boxplots (representing summaries of the signal 
intensity distributions of the arrays, figure 5.1) or a heatmap (representing the distance 
between arrays, figure 5.2).  The detected arrays are outliers and if used may 
compromise the accuracy of final output gene expression data. 
 
Figure 5.1 Box plot of individual normalised microarray data (log2 Ratio of red and Green 
channels).  The microarray for 9BaselineTreatmentA was identified as an outlier. 
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Figure 5.2. False heat map of distance between microarrays. Outlier detection was performed by 
looking for arrays for which the sum of the distances to all other arrays was exceptionally large.  
In this analysis array 5 (corresponding to patient 9 Baseline treatment (A) was identified as an 
outlier. 
 
Patient 9’s microarray data was therefore excluded from analysis as it failed both quality 
metrics. 
 
5.3 Gene Expression 
Microarray data pre-processing (discussed in chapter 2.4 methods) was performed prior 
to differential gene expression.  Differential gene expression during ambulatory oxygen 
and air treatments was explored using the Significance Analysis of Microarrays 
(SAM)(240) in R.  The SAM package allocates a score to each gene on the basis of change 
116 
 
in gene expression relative to the standard deviation of repeated measurements. In cases 
where genes with scores greater than an adjustable threshold occur SAM uses 
permutations of the repeated measurements to estimate the percentage of genes 
identified by chance (false discovery rate, q value).  A two-class paired analysis (i.e. 
comparing oxygen vs. treatment in the same patients) was undertaken. 
At a single gene level differential expression between ambulatory oxygen and air was 
not detectable. 
Since differential expression at a single gene level was not detectable, for the purpose of 
gene set enrichment analyses (GSEA) all genes that were up or down regulated during 
each intervention period were extracted.  A pre-ranked gene list based on the SAM score 
was then used for GSEA in the web based program BROAD(241, 242).  The SAM score was 
chosen over fold change for the formation of the pre-ranked list. Although fold change 
analysis may yield more reproducible gene expression data(243, 244) it does not take into 
account the variance of the expression values measured.  The SAM score compares the 
difference in mean expression levels between two groups also taking into account the 
variability of the data not only from the gene tested, but also from other genes exhibiting 
a similar degree of change(245).  This results in more accurate inference of gene 
expression change when the number of replicates is small(246). 
11,479 genes were identified (gene list of top 400 genes in appendix 3 for GSEA.  Positive 
values correspond to genes up-regulated during Treatment period A (Air) whilst negative 
values correspond to up-regulated genes during Treatment Period B (Ambulatory 
oxygen). 
117 
 
5.3.0 Gene Set Enrichment Analysis (GSEA) 
 
GSEA was performed using the web based program BROAD Institute(241, 242).  GSEA is a 
computation method that determines whether a priori set of genes show significant 
differences between two biological or phenotypic states.  Genes are ranked based on 
their correlation between their expression and in this case the biological states or air and 
AOT.  The aim of GSEA is to determine whether the genes are randomly distributed or are 
dichotomised to the top or bottom of the list.  The latter occurs in genes which 
demonstrate biological or phenotypic distinction.  GSEA has 3 core processes which are 
used to derive its results; enrichment score calculation, estimating the significance of 
enrichment scores and adjustment for multiple hypothesis testing(241, 242). 
Enrichment Score 
 
“The enrichment score (ES) determines the degree to which a gene set is represented at 
the extremes of a ranked list”.  The calculation is made by walking down the list 
increasing a running sum statistic (magnitude depending on correlation between gene 
and phenotype) when the gene is encountered in the set or decreasing it when it not 
encountered (241, 242).  Thus scores which are highly negative or positive are likely to 
demonstrate highly represented gene sets. 
Significance of Enrichment Score 
 
The statistical significance of enrichment score is based on an empirical phenotype based 
permutation test.  A null distribution for the enrichment score is generated by permuting 
data for the phenotypes i.e. oxygen versus air and computing the enrichment score of the 
gene sets for this data.  “The statistical significance of the observed score is then 
calculated relative to the null distribution”(241, 242). 
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Adjustment for multiple testing. 
 
The enrichment score for each gene set is normalised (NES) to account for the size of the 
set. 
 
 
 
The false discovery rate (FDR) is then calculated for each NES.  The FDR is the estimated 
probability that a gene set with a given NES signifies a false positive finding(241). 
 
The gene sets used in the analyses were derived from the Kyoto Encyclopaedia of genes 
and genomes (KEGG) which are a manually curated list of genes. These KEGG pathways 
indicate current knowledge of molecular interactions or networks for various metabolic 
and cellular processes.  The output from BROAD indicate which gene sets for individual 
KEGG pathways were up or down-regulated for the phenotypes (air versus oxygen) when 
the pre ranked list of identified genes were used (appendix 3).  Disease specific pathways 
were removed from the KEGG analysis to optimise biological interpretability of the 
results.  To undertake GSEA using Broad, KEGG version 5.0 was used as the gene set 
database, collapse data set option was set to false as the up/down regulated probes had 
already been annotated with gene symbols as part of the pre-processing (chapter 2.4) 
and the weighted scoring system for enrichment was applied.   
 
NES    =       actual ES 
Mean (ESs against all permutations of dataset) 
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5.3.1 GSEA Results 
The results of the GSEA analysis using KEGG pathways are shown in table 5.2a and 5.2b. 
 
KEGG pathway Size of 
Gene Set 
ES NES FDR q 
value 
RIBOSOME 82 -0.75 -3.62 0 
OXIDATIVE_PHOSPHORYLATION 117 -0.58 -2.96 0 
PROTEASOME 42 -0.67 -2.78 0 
SPLICEOSOME 104 -0.51 -2.57 0 
PROPANOATE_METABOLISM 28 -0.66 -2.49 0 
AMINOACYL_TRNA_BIOSYNTHESIS 27 -0.64 -2.42 0 
FATTY_ACID_METABOLISM 34 -0.62 -2.40 0 
RNA_DEGRADATION 41 -0.58 -2.36 0 
UBIQUITIN_MEDIATED_PROTEOLYSIS 96 -0.48 -2.36 0 
VASOPRESSIN_REGULATED_WATER_REABSORPTION 32 -0.59 -2.31 1.62E-04 
FOCAL_ADHESION 160 -0.41 -2.19 1.52E-04 
PYRUVATE_METABOLISM 34 -0.56 -2.18 2.58E-04 
ADHERENS_JUNCTION 57 -0.48 -2.17 2.44E-04 
NEUROTROPHIN_SIGNALING_PATHWAY 100 -0.42 -2.10 6.80E-04 
ANTIGEN_PROCESSING_AND_PRESENTATION 64 -0.46 -2.10 6.46E-04 
VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION 37 -0.52 -2.10 6.16E-04 
INSULIN_SIGNALING_PATHWAY 114 -0.40 -2.07 0.001261 
LYSOSOME 90 -0.42 -2.01 0.001882 
CITRATE_CYCLE_TCA_CYCLE 26 -0.55 -2.01 0.001814 
NUCLEOTIDE_EXCISION_REPAIR 36 -0.49 -1.96 0.002849 
GLYCOLYSIS_GLUCONEOGENESIS 50 -0.45 -1.93 0.003951 
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TGF_BETA_SIGNALING_PATHWAY 60 -0.42 -1.92 0.004215 
PURINE_METABOLISM 109 -0.37 -1.89 0.005972 
PPAR_SIGNALING_PATHWAY 53 -0.42 -1.85 0.007892 
TRYPTOPHAN_METABOLISM 32 -0.48 -1.85 0.007679 
REGULATION_OF_ACTIN_CYTOSKELETON 163 -0.34 -1.84 0.008137 
 
 
Table 5.2a Enriched KEGG pathways up-regulated during ambulatory oxygen treatment 
KEGG pathway Size of Gene 
Set 
ES NES FDR q value 
OLFACTORY_TRANSDUCTION 125 0.27574 2.04 0.01992 
 
Table 5.2b Enriched KEGG pathway up-regulated during air treatment. 
Enrichment plots for the top two KEGG pathways up-regulated during ambulatory oxygen 
treatment and the KEGG pathway up-regulated during air treatment are shown below 
(figures 5.3a-5.3c). 
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Figure 5.3a. Enrichment plot for KEGG ribosome pathway    
The enrichment plot for the ribosome pathway shows the primary genes involved towards the bottom end 
of the list. The enrichment score is the furthest deviation from zero shown here at the lowest point of the 
plot; score -0.75 (scale -1 to 1).  The “leading edge subset” of a gene set are the genes which contribute 
most to the enrichment score.  The rank at max is a metric which measures a genes correlation with a 
particular phenotype, in this case AOT and is the position in the ranked list at which the maximum 
enrichment score was achieved.  
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Figure 5.3b Enrichment plot for KEGG oxidative phosphorylation; up-regulated during oxygen treatment. 
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Figure 5.3c Enrichment plot for the only KEGG pathway up-regulated during air 
The rank at max in this enrichment plot corresponds to the positive genes in the set (during air treatment).  
In contrast to the leading edge subsets in figures 5.3a-b the subset in this enrichment plot is broad and not 
concentrated at either end ranking generally indicating a poorly represented gene set. 
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The enrichment plots for both Ribosome and Oxidative phosphorylation show gene set 
correlations towards the bottom of the list with a relatively tightly packed leading edge 
subset; particularly in the case of KEGG ribosome. Both have relatively high enrichment 
scores (max -1 to 1).  In contrast the KEGG pathway of olfactory transduction; although 
significant has low enrichment score with its leading edge genes distributed throughout 
the list. 
27 KEGG pathways met the FDR<1% cut off.  26 enriched pathways were up-regulated 
during oxygen treatment whilst only 1 KEGG pathway was up-regulated during air 
treatment (table 5.3b).  The enriched KEGG pathways up-regulated during ambulatory 
oxygen treatment could be clustered into three functional groups; mitochondrial 
bioenergetics, protein turnover and metabolic pathways (figure 5.4). 
 
Figure 5.4: Functional grouping for KEGG pathways upregulated during oxygen treatment. 
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The mitochondrial bioenergetic pathway of oxidative phosphorylation (OXPHOS) was 
chosen for further examination due to (a) its biological relevance and (b) being in the top 
two enriched pathways. A correlation based analysis was conducted with the patient 
clinical outcome data using principal components as described below. 
5.4 Principal component analysis 
Principal component analysis is a data reduction technique.  Using a mathematical 
algorithm it reduces the dimensionality of a data set whilst retaining as much of the 
possible variation within it.  It accomplishes this by identifying the directions (principal 
components) in which the variation in the data is maximal.  When applied to microarray 
data it can be used to perform cluster gene analysis, find dominant patterns of gene 
expression or to summarise transcriptional activity of a “gene set”.  Here it has been used 
to summarise the transcriptional activity of the KEGG oxidative phosphorylation pathway.  
This was achieved by using the “prcomp” function in R (239) taking the normalised 
microarray data and genes from the leading edge subset of the OXPHOS pathway to 
compute the first principal component.   
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Figure 5.5: Plot of principal components against variance:   
 
The red vertical line shows the cut off for the component that accounts for the most 
variance; the first principal component retained 86% of the variance.  This indicates that 
the transcriptional state of the involved genes in the OXPHOS pathway can be 
summarised by this variable. The diagram below is a biplot (fig 5.6); a visual 
representation of the two principal components, microarray observations and the 
OXPHOS genes as vectors (red). The first principal component (PC) is in the horizontal axis 
and second component on the vertical axis.  The genes involved are predominantly 
moving along the horizontal axis (1st PC) highlighting again that the 1st PC account for the 
majority of the variance.  
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Figure 5.6:  Biplot of OXPHOS gene and principal components. 
The biplot can also be used to analyse which patients (microarray observations) 
demonstrated a response to treatment in line with the summarised OXPHOS pathway.  
The major transcriptional direction of vector (genes) is from right to left.  Each patient has 
two microarray observations on the biplot corresponding to Treatment A (Air) and B 
(oxygen).  The patients where whom their “B” observations lie to the left of the “A” 
indicate a greater transcriptional change occurred during oxygen treatment.  This 
suggests that there were 4 responders (subjects 7, 18, 20, 24) and 3 non responders 
(subjects 3, 10 and 13) to ambulatory oxygen therapy.  This is also evident from the 
heatmap of the gene enriched the OXPHOS pathway (figure 5.7).  Analysis of baseline 
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characteristics between these two groups did not demonstrate any significant differences 
between lung function, age, BMI or systemic inflammation (p>0.05).   
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Figure 5.7 Heatmap of genes enriched in OXPHOS pathway: Patient arrays horizontal and genes listed 
vertically. 
Red-indicates increased expression, blue reduced expression and white mean. 
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A correlation based analysis using Spearman’s Rank was undertaken between 
transcriptional activity of the OXPHOS pathway and patient clinical outcomes (table 5.3a) 
for those who underwent muscle biopsies. Pearson’s correlation test (adjusted for age 
and FEV1%) was used to assess the strength of the relationship between transcriptional 
activity and clinical data with one tailed hypothesis significance testing. 
The results are shown in table 5.3b below. 
 
131 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3a:  Clinical outcome data for trial patients whom underwent muscle biopsies.  Results shown are change from trial enrolment baseline for each 
clinical variable in each of the subjects.
Subject ∆6MWT 
Air                 O2 
∆CAT 
Air           O2 
∆HAD 
Air             O2 
∆IL-6pg/ml 
Air             O2 
∆IFN- γ pg/ml 
Air                   O2 
∆IL-8pg/ml 
Air                 O2 
∆TNF-α pg/ml 
Air                 O2 
3 38 167 9 16 -9 -5 -2.43 -0.19 -37.35 127.80 2.27 -0.84 -0.07 -0.06 
7 0 199 8 0 -1 0 -12.21 -49.69 -38.41 -85.52 3.15 -0.51 0.03 0.01 
10 97 93 -4 -4 -5 -6 7.96 -13.23 135.95 -78.45 2.15 0.76 0.23 0.00 
13 -9 73 4 0 -3 -8 -5.91 -2.49 18.15 8.28 -0.19 1.27 0.42 0.27 
18 -60 -54 1 -1 0 3 27.90 -12.66 198.29 94.76 1.13 1.99 0.02 0.03 
20 65 66 7 -2 -1 -4 4.25 1.97 93.32 44.28 3.28 -0.09 -0.09 -0.09 
24 39 78 0 -8 -6 -6 4.22 -9.93 -64.36 24.32 -1.14 -0.38 -0.03 -0.17 
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Clinical outcome Oxygen 
r                     p value 
Air 
r                 p value 
6MWT 0.75               p=0.07 -0.70           p=0.09 
CAT 0.50               p=0.20 0.18            p=0.38 
HAD 0.60               p=0.14 0.64           p=0.12 
Il-6 -0.81             p=0.05 0.42           p=0.24 
Il-8 0.15               p=0.41 0.28           p=0.32 
IFN -0.36             p=0.27 0.25           p=0.35 
 
Table 5.3b: Correlation of OXPHOS pathway and patient clinical data using Spearman’s Rank. 
 
The strongest correlation between clinical variables and transcriptional activity of 
OXPHOS pathway was IL-6 during ambulatory oxygen treatment; showing a significant 
inverse relationship, p=0.05. 6MWT and OXPHOS activity showed a strong relationship 
during both treatments; strongly positively correlated during oxygen treatment and a 
strong inverse relationship during air treatment. 
A hypothetical interaction between selected genes contributing to KEGG pathways, 
KEGGS pathways, cytokine and clinical outcomes is shown in figure 5.8. 
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Figure 5.8 Interaction between KEGG pathways, genes and clinical data. 
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5.5 Discussion 
 
This work has shown that although differential expression at single gene level is absent, 
GSEA demonstrates important up-regulated pathways involving aspects of mitochondrial 
function which accompanied ambulatory oxygen treatment.  Skeletal muscle 
mitochondrial function has been shown to be abnormal in COPD, with respect to both 
reduced mitochondrial density and biogenesis (139, 247).  Mitochondria are the main 
producers of ATP via the Tricarboxylic acid cycle (TCA) and OXPHOS and constitute one of 
the main producers of reactive oxygen species (ROS), which activate pathways leading to 
cell apoptosis (118, 248).  Thus, defects in mitochondrial function will adversely affect 
both energy production and cell death.  The results from our analysis indicate that 
hypoxia maybe contributing to the abnormal mitochondrial function in the studied 
patients.  Furthermore a previous study (153) which used a systems biology approach to 
elucidate the potential drivers for skeletal muscle abnormalities found that at an 
individual gene level a number of histone deacetylase enzymes could discriminate 
between healthy and diseased muscle; all of which correlated with oxygen utilization.   
Under hypoxemic conditions hypoxia inducible factor alpha (HIF-α) is up-regulated due to 
reduced protein degradation by the von Hippel Lindau Protein (249). HIF-α has been 
shown to suppress the peroxisome proliferator activator receptor (PPAR) pathway (250), 
one the key exponents of mitochondrial oxidative metabolism.  Activation of PGC1-α 
(peroxisome proliferator activator receptor γ cofactor α) up-regulates genes involved in 
the TCA cycle and OXPHOS via nuclear respiratory factors 1 and 2. (251).  Both OXPHOS 
and TCA are oxygen dependent and were significantly up-regulated during oxygen 
treatment compared to that of air in the KEGG pathway GSEA analysis.  This is in line with 
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other studies which have used biomarkers of TCA and OXPHOS function; citrate synthase 
and complex III respectively to show these are reduced during hypoxia (252, 253).   The 
enriched pathways during AOT could be manually separated into three functional groups 
(figure 5.4) there is a degree of overlap between groups 1 and 2.  For example, in beta 
oxidation a component of fatty acid metabolism generates acetyl-coA and NADPH 
(nicotinamide adenine dinucleotide phosphate) which enters the TCA cycle and electron 
transport chain respectively (254).  Evidence from both human and murine studies 
suggests that there is a tendency for beta oxidation to be reduced following hypoxic 
stimuli and as a consequence reducing mitochondrial energy production (253, 255).  The 
last functional group of protein turnover indicate that both pathways of protein synthesis 
and protein degradation were significantly up-regulated during oxygen treatment.  Whilst 
protein synthesis is important in gaining muscle mass it is interesting that the ubiquitin 
proteasome pathway (UbP) is also up-regulated.  This is the key proteolytic pathway 
which underpins muscle atrophy.  Cross sectional studies have shown markers of the 
UbP, specifically MuRF1 (muscle ring finger protein) and Atrogin 1, to be elevated in 
COPD patients with low muscle mass compared to controls (127).   The up-regulation of 
both pathways during oxygen treatment suggests that muscle mass homeostasis is tightly 
regulated and the genes involved in this process are differentially affected by hypoxia.  
Alternatively, it is possible that fibre type-specific changes–atrophy in Type II and 
maintenance in Type I – produce simultaneous up-regulation in both protein synthesis 
and degradation genes. The only KEGG pathway up-regulated during air treatment to the 
FDR threshold of <1% was olfactory transduction.  The reasons for this pathway being up-
regulated are not clear.  It has no relationship to muscle function or mitochondrial energy 
production.   
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The correlations between OXPHOS transcriptional activity and clinical data were generally 
strongest during AOT.  The significant inverse relationship between IL-6 and OXPHOS is 
interesting.  This suggests that the cellular process of OXPHOS is deleteriously affected by 
increasing levels of IL-6.  Given that, IL-6 was also significantly reduced compared to 
baseline during AOT, the relationship between inflammation (especially this cytokine) and 
impaired cellular mitochondrial process seem highly plausible.  A previous study also 
demonstrated a significant relationship between systemic inflammation and the 
expression of energy metabolism genes in skeletal muscle from COPD patients, where 
CXCL10 and CXCL9 were significantly inversely correlated to the OXPHOS and TCA 
pathways(256).  Van den Burst et al(257) previously demonstrated a relationship 
between loss of muscle oxidative phenotype and reduced endurance in patients with 
COPD.  This is supported by the correlations we observed between functional exercise 
capacity and OXPHOS transcriptional activity during both treatments.  During the air 
treatment phase i.e. “control arm” an inverse relationship was noted suggesting that 
continued hypoxia during exertion had a negative impact on OXPHOS.  The reverse was 
true during AOT.  
There are a number of limitations to these results.  Primarily, the sample size used for the 
microarray data analysis was small.  Only 8 of the 17 patients underwent muscle biopsies 
that could be used in the microarray data analysis at all-time points, due to the 
unavoidable factor of patient refusal. Overall recruitment to the trial was extended to 
account for dropouts, but due to time and funding constraints no additional amendments 
to extend recruitment and account for these refusals could be justified, given that the 
number who might be needed was not known.  This is because no formal power 
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calculations were undertaken, as the exploratory endpoint of change in gene expression 
had never been measured previously with respect to treatment with oxygen therapy.  
Nevertheless previous studies using gene expression in muscle as an endpoint have 
demonstrated differences with a few as 10 patients (173), hence why a pilot of this size 
was justifiable.  Analysis of the participants who completed muscle biopsy compared to 
those who continued in the trial with secondary outcome data show that they do not 
differ significantly with respect to age p=0.91, FEV1% p=0.85, baseline 6MWT p=0.92 , 
oxygen saturations p=0.2, desaturation nadir p=0.34 or baseline BMI p=0.88.  Therefore, 
although the dropout rate from was higher than expected the sample included was 
representative of all trial participants.  The correlation gene expression analyses were 
single tailed which can lead to inaccurate of biased results.  Nevertheless, the 
associations demonstrated have been supported by previous literature(256, 257) and 
thus warrant further investigation.  
Gene set enrichment analysis was performed on the resulting microarray gene results as, 
after correcting for multiple hypotheses testing, no individual gene met the threshold for 
statistical significance.   GSEA is useful in this context as small changes in a number of 
genes encoding the same pathway may have more biological relevance to a cellular 
process than a single gene(241) especially if  the changes in the studied biological system 
are subtle. GSEA is a robust and commonly used tool to further explore microarray data 
in the presence or absence of identified genes.  
Conclusion 
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Ambulatory oxygen treatment did not result in detectable statistically differentially 
expressed genes after correction for multiple hypotheses testing.  Although differential 
expression was undetectable GSEA analysis revealed important pathways of 
mitochondrial bioenergetics that were up-regulated in muscle following ambulatory 
oxygen treatment suggesting that intermittent hypoxia is likely to be contributing to 
abnormal mitochondrial function in these patients.  In addition use of computational 
analysis reveal of a significant inverse relationship between levels of inflammation and 
oxidative phosphorylation suggesting a potential link between systemic inflammation and 
aberrant mitochondrial function. Analyses were limited by the size of the population 
studied and their relative inactivity, such that periods of hypoxia due to activity may have 
been infrequent and short in duration. 
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Chapter 6 Discussion Summary 
6.1 Summary of Results 
 
This thesis concerns the role of ambulatory oxygen in patients with COPD and exercise 
induced desaturation.  It specifically assesses its clinical efficacy with regard to exercise 
capacity, quality of life, clinical device efficacy and effect on skeletal muscle gene 
expression via the randomised clinical trial: detailed in chapter 4. 
6.2 Clinical efficacy 
 
Ten studies including OM COPD evaluated the role of AOT to improve exercise capacity.  
The modality of the exercise test and the context in which the test were carried out 
varied.  Five of the studies were supervised; associated with a structured exercise 
program, whereas the rest were domiciliary with instructions given to patients when to 
use AOT. It is therefore important to understand that due to the heterogeneity of the 
studies included firm conclusions with regard to AOT clinical efficacy may be limited.  
Functional exercise capacity was measured by 6MWT in the majority of studies which did 
not use endurances tests.  In both supervised PR and domiciliary studies AOT had limited 
benefit of improving 6MWT with all studies bar the OM COPD favouring control.  The 
latter study showed a non-significant improvement in 6MWT with AOT, which may have 
clinical relevance in patients with COPD and EID in relation to mortality from 
hospitalisation.  The magnitude of improvement in functional exercise capacity was far 
greater in the supervised studies than domiciliary.  Clearly the impact of structured 
physical exercise programs and the subsequent physiological adaptation gained from 
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exercise is superior to any benefit gained from AOT.  All of the endurance test studies or 
constant work rate tests were supervised.  Collectively they demonstrate that AOT is 
likely to have benefit in improving endurance/time exercised if judged by this modality 
with all studies favouring the AOT mirrored also in the meta-analyses (chapter 3).  These 
observations taken together suggest either there are different mechanism by which AOT 
affects these different tests or endurance tests are more sensitive to therapies such as 
AOT or both.  The main postulated mechanisms for AOT efficacy are to reduce carotid 
body activation and cause a subsequent reduction in respiratory rate.  Since dyspnoea is a 
limitation to exercise tolerance in patients with COPD, a reduction in respiratory rate and 
sensation of dyspnoea is likely to improve exercise capacity.  A reduction in dynamic 
inflation has also been observed in one study(72).  A number of studies have shown that 
endurance test are more responsive to interventions than the 6MWT when 
bronchodilators have been used(258).  Given that bronchodilators reduce hyperinflation 
in a similar mechanistic fashion to AOT it seems highly plausible that endurance test 
should respond better to AOT than the 6MWT(258).  The design of the exercise tests are 
also very different.  The 6MWT is self paced while endurance tests such as ESWT are 
externally paced (calculated from an externally paced incremental shuttle walk).  
Evidence suggests that the cardiorespiratory response in patients with COPD differ when 
either test is undertaken.  During endurance tests heart rate, minute ventilation and 
respiratory rate increase close to maximal levels whereas these three indices are sub-
maximal during a 6MWT.  One could hypothesize that any treatment which reduces 
dynamic hyperinflation is unlikely to demonstrate benefit if the test used causes a sub-
maximal response especially in respiratory rate and minute ventilation and therefore 
unlikely to evoke a “hyperinflation” physiological threshold. 
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The Chronic respiratory disease questionnaire (CRQ), HADs and CAT examined the impact 
of AOT on HRQoL.  In both supervised PR and domiciliary studies AOT demonstrated 
statistically significant benefit over control when the CRQ was used.  The CRQ covers 
themes such as anxiety, physical function and breathlessness.  The OM COPD trial 
described in chapter 4 used the HAD and CAT which when combined cover similar areas 
to the CRQ.  Whilst a statistically significant improvement in HADs score was noted after 
AOT occurred, a marked improvement in the control arm also occurred, a phenomenon 
often seen in the placebo arm of clinical trials.  Despite the statistical improvement in 
both CRQ and HAD, the clinical relevance is doubtful as all the improvement s in CRQ fall 
below the MCID and no MCID for HADs has been established.  What is clear from the 
results is that AOT seems to give patients the perception that they are less breathless and 
more in control of their disease.  The perception of dyspnoea in COPD is complex, with a 
number of bio-pyschological factors involved.   The apparent benefit in HRQoL may come 
from a number of altered perceptions of safety, symptom relief, possible placebo effect 
and motivational factors. 
6.3 Device Efficacy 
 
The results from chapter 3 indicate that whilst there is considerable variation in OCDs 
devices their performance is superior to CFNC in maintaining exercise saturations and 
6MWT.  The OCDs achieve these outcomes at much lower oxygen utilization than CFNC. 
This is likely to have implications in terms of oxygen cylinder usage and subsequent cost 
as although initial outlay for OCDs is higher the longer term benefit of lower oxygen 
utilisation will more than recoup this.  It is important that the choice of OCDs is tailored 
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to the individual taking into account whether they are predominately mouth or nasal 
breathers as the effort of ambulation or exercise increases.  Since most of the OCDs are 
triggered by nasal inspiratory flow a change to mouth breathing during increased effort 
would render these OCDs less useful and cause desaturation to the user. 
6.4 Changes in Skeletal Muscle gene expression 
 
There is a wealth of data to suggest that skeletal muscle in patients with COPD differs to 
controls with respect to reduction in proportion of type 1 fibres(152), abnormal 
mitochondrial density(133), increased oxidative stress and loss of oxidative 
phosphorylation phenotype(257).  The difficulty has been in trying to determine the main 
driver to these alterations.  Hypoxia is implicated in its pathogenesis.  The pilot clinical 
trial (chapter 4) investigated the role of oxygen supplementation during activity in 
patients with COPD and exercise induced desaturation.  The hypothesis was that 
peripheral muscle hypoxia is increased specifically in these patients on exertion especially 
in those with low activity levels.  Administration of AOT would either encourage 
participants to be more active and via activity have a favourable effect on gene 
expression or have a direct effect on muscle in its own right. Unfortunately at a single 
gene level there was no detectable difference in gene expression between AOT or air 
treatment.  The study aimed to recruit 25 participants however there was a high dropout 
rate due to many participants not being able to tolerate serial muscle biopsies.  Although 
it is unlikely given the results from chapter 4&5 that AOT directly impacts on muscle 
results may have been more favourable had it been the total number recruited were 
involved in the gene expression analysis.  In addition, participant activity was low and did 
not change significantly during the trial indicating that AOT did not encourage 
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participants to become more active.  Furthermore, linked to low activity was low cylinder 
usage during the trial period; equating to roughly 30mins per day.  Given both the low 
activity and cylinder usage it is not surprising that no gene or cytokine changes were 
demonstrated.  Participants were given clear instructions on when and how to use 
cylinders, however a more detailed discussion prior to trial enrolment on the merits and 
rationale for usage should have been undertaken.  Other reasons for absence of 
detectable change in gene expression have been discussed in section 4.2.5.    
The results of the GSEA demonstrate upregulation of multiple mitochondrial and cell 
homeostasis pathways during AOT.  Given that these pathways were not upregulated 
during air treatment the attenuation of hypoxia during exertion would seem to be 
contributing to these changes.  The study by Turan et al(153) also suggested hypoxia as 
the cause for the abnormal response in COPD muscles with an underlying epigenetic 
mechanism.  They were able to show that the expression of a number of oxygen 
correlated histone modifiers could discriminate between healthy and COPD muscle; 
sirtuins and histone deacetylases.  Hypoxia can lead to an altered redox state which has 
been shown to be abnormal in COPD (154, 259).  Sirtuins are NAD+ dependent 
deacetylases and their activity especially SIRT1 and SIRT3 are sensitive to changes in NAD+ 
to NAD+/NADH ratio which is adversely affected by hypoxia. Enhanced SIRT activity, 
namely SIRT3 is associated with improved mitochondrial function and exercise 
performance. Murine studies of mice lacking SIRT3 show abnormalities of a number of 
mitochondrial proteins associated with impaired electron transport chain activity and 
fatty acid metabolism(260). Indeed the transcriptional correlation analysis showed 
strongly positive correlation between OXPHOS and 6MWT during AOT almost reaching 
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statistical significance with the converse was true during air treatment. Collectively one 
could speculate would suggest that hypoxia is implicated in the altered muscle gene 
expression and regulation causing abnormal mitochondrial function indicated by the 
results of the GSEA. 
The results from chapter 4 showed that IL-6 was the only cytokine which demonstrated 
significant change during the clinical trial with reduction in plasma IL-6 during AOT 
compared to baseline values albeit with no between group differences.  The 
transcriptional correlation analysis also showed a significant inverse relationship between 
plasma IL-6 and the mitochondrial OXPHOS pathway suggesting that lower IL-6 levels 
confer enhanced OXPHOS activity.  The role of IL-6 on muscle biology is complex with a 
few studies showing both pro-myogenic and atrophic effects of the cytokine(261).   
Exercise especially endurance or eccentric causes acute inflammation within skeletal 
muscle and studies have shown that IL-6, IL-6 mRNA rise dramatically during acute 
exercise(262).  The adaptations noted following regular exercise lead to reduction of 
oxidative damage and improved mitochondrial biogenesis (largely mediated by PCG-1 α). 
Thus to adapt appropriately episode of acute inflammation during exercise are required. 
Regular exercise may reduce basal IL-6 levels and also the magnitude of response to IL-6 
and the efficiency of the bioenergetic changes(262).  Whilst acute changes seem to be 
beneficial, murine studies have shown that IL-6 over expression can cause mitochondrial 
dysfunction (263) a process which can be rectified with physical activity.  A number of 
epidemiological studies have also shown a negative relationship between physical activity 
and IL-6 levels.  Therefore it is possible that the use of AOT ameliorates basal IL-6 levels 
akin to exercise in the cohort of patients in the study. 
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6.5 Future Work 
 
6.5.0 Ambulatory oxygen Efficacy 
 
The clinical efficacy of AOT in improving exercise capacity is largely dependent on the 
exercise test modality chosen.  The evidence suggests that AOT use does result in 
statistically significant improvements in endurance or constant work rate exercise tests.  
The results from the systematic review would be have been useful to inform the exercise 
modality chosen in the clinical trial (chapter 4).  Although this thesis via the clinical trial 
adds to the evidence that AOT has limited role in statistically improving 6MWT, the effect 
of AOT would have been better assessed by an endurance shuttle walk test which would 
have been achievable at the trial site.  If the 6MWT was to be used in future to assess the 
longer terms benefits of AOT any future trial should only enrol acute responders; i.e. 
participants with 10% improvement in 6MWT following AOT use.   
6.5.1 Inflammatory response to AOT 
 
Inflammation is one of the hypothesized aetiological factors in abnormal muscle function 
predominantly via NfkB activation.  The inflammatory response can either be systemic or 
local.  It is highly plausible that changes in systemic inflammation may not reflect those at 
the muscle level and may indicate a different mechanism. The OM COPD trial did 
demonstrate a significant reduction in plasma IL-6.  It is unclear whether muscle IL-6 
mRNA would show a similar pattern.  It would be important to assess both local and 
systemic inflammation in future studies.   Systemic inflammation could be assessed as 
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described in chapter 2 whilst local inflammation assessed by extracting RNA from muscle 
subsequently using the appropriate probes and primers to quantify this.   
6.5.2 Gene Expression 
 
The pilot study of AOT effect on skeletal muscle gene expression has given some insight 
to how its use may perturb some of the deleterious changes observed in COPD patients.  
Since this study was small and recruitment falling short of target the number of 
participant included in a future similar would need to be significantly larger. Data from 
previous studies(173, 264) indicate that between 200 and 1100 genes maybe 
differentially expressed in exercise in COPD patients or those with reduced fat free mass.  
Assuming approximately 18000 are not differentially expressed genes, 0.9 power to 
detect a fold change of 2 between treatments and an anticipated standard deviation of 
0.6 (matched pair design) (265) a sample size of 19 in each arm would be required.  This 
would firstly help confirm the results from the clinical trial (chapter 4) and may yield 
individual differentially expressed genes.  This information would be used in concert with 
cytokine data to further explore the relationship between hypoxia, inflammatory 
response and changes in gene expression.  The clinical trial work tentatively suggests that 
mitochondrial functions such as oxidative phosphorylation are important in the aetiology 
of muscle dysfunction. As mentioned above one of the key problems with the OM COPD 
trial was recruitment.  This in part may have been due to the number of skeletal muscle 
biopsies participants had to undertake; 3. An alternative approach would use a 
randomised double blind parallel trial of AOT vs Air over a similar time period as the OM 
COPD trial, with muscle again as the primary end point.  However, one would analyse 
target OXPHOS proteins e.g. (complexes 1-4) and also genes of the OXPHOS pathways 
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such as PGC-1 alpha, PPAR from skeletal muscle at baseline and at the end of the trial.  
The analysis of target proteins may prove more fruitful as one would expect any change 
from AOT usage to be over a period of weeks/month.  In contrast changes in relative 
expression of genes involved in mitochondrial or muscle hypertrophy occur over hours to 
a day following sufficient stimuli e.g. exercise.  
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Appendix 1 
 
Search Strategy –Clinical and DeviceEfficacy 
1. chronic obstructive pulmonary disease/  
2. copd.mp.  
3. smoking-related lung disease$.mp.  
4. lung emphysema/  
5. exp bronchitis/  
6. (chronic respiratory adj (disease or disorder)).mp. [mp=title, abstract, subject headings, 
heading word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword]  
7. (chronic obstructive lung adj (disease or disorder)).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword]  
8. (chronic obstructive pulmonary adj (disease or disorder)).mp. [mp=title, abstract, 
subject headings, heading word, drug trade name, original title, device manufacturer, 
drug manufacturer, device trade name, keyword]  
9. (chronic obstructive airway adj (disease or disorder)).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword]  
10. (chronic obstructive respiratory adj (disease or disorder)).mp. [mp=title, abstract, 
subject headings, heading word, drug trade name, original title, device manufacturer, 
drug manufacturer, device trade name, keyword]  
11. chronic ventilatory failure.mp.  
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11  
13. oxygen therapy/  
14. exp ambulatory care/  
15. 13 and 14  
16. ((ambulat$ or portable or supplemental or O2) adj2 (oxygen or therap$)).mp. 
[mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword]  
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17. 15 or 16  
18. 12 and 17  
 
 Search Strategy –Cost effectiveness  
1 chronic obstructive lung disease/ (67861)  
2 copd.mp. (37001)  
3 smoking-related lung disease$.mp. (97)  
4 lung emphysema/ (14765)  
5 exp bronchitis/ (45660)  
6 (chronic respiratory adj (disease or disorder)).mp. [mp=title, abstract, subject headings, 
heading word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword] (1569)  
7 (chronic obstructive pulmonary adj (disease or disorder)).mp. [mp=title, abstract, 
subject headings, heading word, drug trade name, original title, device manufacturer, 
drug manufacturer, device trade name, keyword] (34872)  
8 (chronic obstructive lung adj (disease or disorder)).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] (68620)  
9 (chronic obstructive airway adj (disease or disorder)).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] (337)  
10 (chronic obstructive respiratory adj (disease or disorder)).mp. [mp=title, abstract, 
subject headings, heading word, drug trade name, original title, device manufacturer, 
drug manufacturer, device trade name, keyword] (106)  
11 chronic ventilatory failure.mp. (92)  
12 or/1-11 (130339) 
13 oxygen therapy/ (19975)  
14 exp ambulatory care/ (38150)  
15 13 and 14 (123)  
16 ((ambulat$ or portable or supplemental or O2) adj2 (oxygen or therap$)).mp. (9268)  
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17 15 or 16 (9324)  
18 12 and 17 (932)  
19 cost benefit analysis/ (65629)  
20 cost effectiveness analysis/ (90660)  
21 cost minimization analysis/ (2303)  
22 cost utility analysis/ (4841)  
23 economic evaluation/ (8349)  
24 (cost or costs or costed or costly or costing).tw. (403593)  
25 (economic$ or pharmacoeconomic$ or price$ or pricing).tw. (210580)  
26 (technology adj assessment$).tw. (4263)  
27 or/19-26 (614168) 
28 18 and 27 (95) 
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CONSENT FORM  
Study Number: ERN-11-1670 
Patient Identification Number for this trial:  
Title of Project:  
Name of Researcher:  
Please initial box  
I confirm that I have read and understand the information sheet dated....................  
version............for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily.  
 
 
I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my medical care or legal rights being 
affected.  
 
 
I understand that relevant sections of my medical notes and data collected during 
the study, may be looked at by individuals from the University of Birmingham, from 
regulatory authorities or from the NHS Trust, where it is relevant to my taking part 
in this research. I give permission for these individuals to have access to my records.  
 
 
I agree to my GP being informed of my participation in the study.  
 
 
I agree to take part in the above study.  
 
 
 
Name of Patient ………………………………………………………………………………………..  Date………………….. 
 Signature……………………………………………………………………………………………………………………………………  
Name of Person taking consent …………………………………………………………………  Date…………………… 
Signature……………………………………………………………………………………………………………………………………. 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical 
notes. 
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Appendix 2.8 
Can muscle dysfunction in COPD be altered by oxygenation in patients with intermittent 
hypoxia on exertion? 
 
Proforma Visit 0 
Patient ID         D.O.B                      
Age  
Sex   Male    Female 
 
O2 sats               
 
ABG (0.21)             
  
 Measured Predicted %Predicted Lower Limit 
FEV1     
FVC     
 
Chronic bronchitis 
Emphysema 
Bronchiectasis 
Common comorbidities: IHD          DM             Heart failure (R or L)         Osteoporosis          GORD   
MRC dyspnoea score 
 
CAT score 
 
HAD score 
Anxiety 
Component 
            /21 
Depression  
Component 
            /21 
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6MWT Distance  
 
 
Samples collected 
Serum sample Results 
 
 
 
 
 
Activity monitor data 
Activity Level Time Spent per Day Hours:mins 
Day 1 2 3 4 5 Ave 
Sedentary       
Light       
Moderate       
Vigorous       
Total       
 
 
Proforma for clinic visits 14, 28, 34 and 35 would be broadly similar 
Extra information collected at those time points: 
 
ADVERSE EVENTS 
Recent exacerbation requiring hospital admission  Y  N 
Recent exacerbation treated in community   Y  N 
Adverse event 
Clinic visit wk8 and 22 would just include (HAD, CAT and extra info collected as above). 
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Appendix 3 
KIAA0355 TOMM20 RASSF1 AKT2 
ING1 JDP2 ACAD9 DOK1 
WARS PSMD6 DYNC1LI2 LMBRD1 
USP1 KLHDC2 XLOC_010470 DROSHA 
SAC3D1 IGSF8 TPPP ARFIP1 
LZTS2 BST2 CELF5 ADIPOR1 
PNKD USP35 RNF130 MXD4 
XLOC_014512 MYADM SURF4 EMC4 
TGFB1 CRIP1 DDX49 BNIP3L 
RPS6KA2 SLC40A1 C1QA TMEM221 
TRAP1 CRNDE INTS10 PHYHD1 
XLOC_007868 CTNS MRC2 SNRPF 
COL1A2 C11orf83 PDXK FTL 
SPON2 FAM174B LOC101927712 NOB1 
SYT6 AHNAK2 TBC1D9B GPATCH3 
LRRC8A IRF2BPL FBXO10 NDUFAF6 
LOC102725379 SERPINB1 UBE2H PREP 
RAB31 GOLGA3 PEA15 SETBP1 
ARPC5 C20orf24 PLEKHB2 DPCD 
LARP6 LOC101928089 CDC123 EHD2 
PLOD1 LFNG COPRS LIG1 
AGMAT KANSL1 SND1 ZNF667-AS1 
GZMA TKT C2orf47 TMEM59 
SLC25A39 SMIM4 XLOC_013142 TMEM11 
BCL2L1 COL4A3BP RNPEP MCFD2 
CDK11A FLNA SSNA1 RPRML 
SZRD1 GUCA2B MRPS11 C1orf174 
BCAP31 USP38 LGALS3 XLOC_004260 
NSUN5 TTC40 AP1B1 NUPR1 
REST EMC8 TXNRD3 PNPLA2 
CEP63 LRRD1 AKR1C3 SUMO2 
ATP6V0A1 GPATCH4 DPP7 FAM71E1 
SLC14A1 C2orf88 XLOC_008233 TRADD 
SMAD4 AVPI1 ARAP1 GPBP1 
ZNF189 CDR1 MET PI16 
CTDP1 SSR1 IGFBP5 LINC00943 
PMPCA MMGT1 PHLDB1 RANBP9 
UGDH BCL2 RBM17 XLOC_003147 
GPKOW HIST1H3I TBX1 FNDC1 
C5orf22 TMEM120A PEAK1 MIR143HG 
ALDH3A2 EBLN3 EML4 SARNP 
TAPBP CCDC22 CHRDL1 MRPL54 
NUP85 C16orf58 RAI1 RPS17 
KEAP1 RAB5C VSTM4 VMA21 
TAOK3 FAM120AOS PRMT2 CYHR1 
FRA10AC1 GADL1 ABCD1 SCPEP1 
CYB5A TMEM237 ADAR RGCC 
WDR61 LOC390705 ZFAS1 ACACB 
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KIAA0226 TUBA1C CCDC3 MGLL 
FAM213A IL15 ENDOD1 LMAN2 
CHCHD7 ATP2B4 FAM20B HYI 
TOR1AIP2 F8A1 HSP90B1 RAP1GAP2 
TOR1AIP1 NUDT1 MTERFD2 RMDN3 
MRPS30 NCAM1 SLC39A3 SNCB 
BBX GUCD1 HPS1 ARHGEF11 
BCKDHB NFIL3 REXO2 URGCP 
CSF1R PMVK SLC43A3 EPB41L4A-AS1 
AIMP1 PPP1R8 TNXB PLIN1 
LPL ATRAID RAB11B RAB3GAP1 
CROCC BTBD9 RPL22L1 ITIH5 
MRPL10 SPTAN1 PTPN2 TMEM204 
GNE MICU1 EGFR-AS1 RAPGEF1 
YIPF6 GPX4 C6orf226 TLE2 
NDRG1 TMEM43 PLEKHO2 AKR1C1 
FTO HLA-DPB1 USP22 TMSB4X 
C1orf43 TCF25 HTRA1 MRPL36 
KANK2 SNORD38A TRIM24 S100A13 
MTDH SLC25A6 PSEN2 TLN1 
MARS LRRC8C LYRM4 DDI2 
RNF149 DNPH1 KANK3 KCNS3 
STK19 GGT5 LRRC59 HERC2P4 
ZNF32 BTBD1 COL1A1 C10orf71-AS1 
TMEM110 DHCR24 C22orf34 SUCO 
ZFAND3 ARNT2 PFKFB3 CAV1 
ISLR CMTM3 HTRA2 DAG1 
SELENBP1 MRPL45 COQ5 XRCC5 
PTPN6 GUK1 LINC00657 GPX1 
C12orf4 HAS3 FBXO7 ARHGDIA 
COBL LPCAT1 ORMDL2 OR3A3 
IFI27 RPA3 LOC440864 MLLT4 
HSPG2 YME1L1 HIST1H4I BARD1 
SPDYE4 NPC2 PTPN18 SIDT2 
NT5C TTC33 SKIV2L2 ZNF174 
SERPINE1 RPL13A ADPRHL1 C20orf166-AS1 
EIF1AX FHL2 SRRT LYPLA2 
RPL28 CTTN XLOC_006689 CNP 
IFITM2 XYLT2 KLHL6 AKR7A2 
MN1 KIAA1549L PPP2R2D SEPP1 
MEF2A KEL SH3GL1P2 LOC100507144 
PITX2 FOXP1 KARS ECSIT 
LSP1 SCAND1 NAA10 CHTF8 
CHSY1 CYBA MEDAG STX2 
NUCB2 ACTR3C HIST1H2AC FECH 
IFI30 MARCKS COA3 MUM1 
CCDC6 GNG10 SNCA XLOC_007433 
HIGD2A SEPN1 PBX1 USP4 
CAT MRPS6 LRP1 ZCCHC24 
YPEL5 STRADB AQP7 SLC25A46 
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CRELD1 TMSB10 CCDC80 COL6A4P2 
POLR2C STT3A DHDDS EHMT1 
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